Introduction {#s1}
============

Energy supply is a fundamental requirement for all cells to perform their biochemical functions. Universally, ATP is the single most important energy-supplying molecule in every form of life. ATP regeneration from ADP takes place in mitochondria mainly through OxPhos, and in the cytosol through glycolysis. Despite its heavy demand for ATP to facilitate protein folding and trafficking, the ER is not known to possess an independent ATP regeneration machinery. A membrane protein, '*ER-ANT*', is involved in the ATP translocation across the ER membrane, of which the biochemical properties are analogous to the mitochondrial **A**denosine **N**ucleotide **T**ransporter (**ANT**) ([@bib7]; [@bib34]). Other than that, little is known about how ATP gets into the ER in a living cell or whether/how ATP consumption is regulated in the ER lumen. For example, only one report described the genetic identification of an ATP transporter *ER-ANT1* in *Arabidopsis* which is restricted to plants and its deletion caused a disastrous plant phenotype, characterized by drastic growth retardation and impaired root and seed development ([@bib18]). The mammalian ER ATP transporter remained elusive until a recent publication identified SLC35B1/AXER as the putative mammalian ER ATP transporter ([@bib15]).

ER ATP is essential to support protein chaperone functions for protein folding, such as BiP/GRP78, and trafficking ([@bib10]; [@bib4]; [@bib11]; [@bib41]; [@bib28]). In fact, the level of ER ATP determines which proteins are able to transit to the cell surface ([@bib10]; [@bib11]). Although the level of ER ATP is suggested to impact protein secretion, this has not been demonstrated, nor have the factors that regulate ATP levels in the ER been clearly elucidated, although an association with ER Ca^2+^ pool was suspected ([@bib39]; [@bib15]). More recently, organelle specific ATP status determination was made possible with the genetically encoded FRET-based ATP reporter proteins targeted to select intracellular organelles, namely the mitochondrial localized *AT1.03* and the ER localized *ERAT4* probes ([@bib13]; [@bib39]). A recent study revealed that the regulation of mitochondrial matrix ATP is highly dynamic and complex ([@bib8]). Here, we studied ATP dynamics within the ER organelle in intact cells. Specifically, we monitored real-time changes in ATP levels inside the ER lumen in response to well-characterized OxPhos and/or glycolysis inhibitors in living Chinese hamster ovary (**CHO**), rat insulinoma INS1 and human Hela cells, at the single cell level using an ERAT-based FRET assay. In addition, we monitored the change in ER ATP upon Ca^2+^ release from the ER, and further evaluated the ER ATP status in response to varying cytosolic Ca^2+^ concentrations. From our findings we propose that cytosolic Ca^2+^ attenuates mitochondrial-driven ATP transport into the ER lumen through a *CaATiER* (**Ca**^2+^-**A**ntagonized **T**ransport **i**nto **ER**) mechanism. This model was further validated by knocking-down *Slc35b1* in HeLa, CHO and INS1 cells, and under conditions of ER protein misfolding in CHO cells.

Results {#s2}
=======

ER ATP comes from Mitochondrial OxPhos in CHO cells {#s2-1}
---------------------------------------------------

Traditional ATP analytical methods based on biochemical or enzymatic assays inevitably require ATP liberation from endogenous compartments, and do not reflect compartment-specific ATP dynamics. Nevertheless, there is ample evidence supporting that differential ATP levels exist in membrane-bound organelles that use independent regulatory mechanisms in a compartment-specific manner ([@bib1]; [@bib8]; [@bib13]; [@bib39]). To detect ATP levels in the ER lumen in vivo, (note that we use in vivo to indicate in a live cell) we expressed an ER-localized ATP sensor ERAT (ERAT4.01^N7Q^) in H9 CHO cells engineered to induce mRNA expression of human clotting factor VIII (**F8**), encoding a protein which misfolds in the ER lumen, upon increased transcription promoted by histone deacetylase inhibition ([@bib9]; [@bib21]). Confocal analysis of ERAT fluorescence ([Figure 1A](#fig1){ref-type="fig"}, green) revealed nearly complete co-localization with the ER marker, ER-Tracker Red ([Figure 1A](#fig1){ref-type="fig"}, red), as well as with the endogenous ER-resident protein PDIA6 detected by immunofluorescence ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Induction of F8 by SAHA treatment, an HDAC inhibitor, for 20 hr did not change the ER localization of the ERAT reporter ([Figure 1B](#fig1){ref-type="fig"}, and [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Another protein ER marker, ER-RFP, also shows nearly complete co-localization with ERAT fluorescence although ER-RFP formed aggregates ([@bib23]) upon SAHA induction ([Figure 1---figure supplement 2A and B](#fig1s2){ref-type="fig"}, with RFP aggregates indicated with yellow arrow heads). As there is no known ATP regeneration machinery in the ER, and intracellular ATP regeneration from ADP takes place in mitochondria through OxPhos, and in the cytosol through glycolysis, it is of key importance to determine whether the ER ATP status depends on OxPhos and/or glycolysis (illustrated in [Figure 1C](#fig1){ref-type="fig"}). For this purpose, we analyzed ER ATP levels after OxPhos inhibition or glycolysis inhibition by monitoring the FRET signal through flow-cytometry, since this technique provides robust population statistics and circumvents photo-bleaching of the fluorescent probes. In order to achieve consistent ATP signal detection from a homogenous population of cells, we further constructed a clone of H9 CHO (*H9-D2* cell) with stably transfected ERAT4.01^N7Q^ reporter ([Figure 1---figure supplement 3A and B](#fig1s3){ref-type="fig"} *versus* C and D). In addition, as inhibition of glycolysis may have adverse effects on OxPhos, we tested whether 2-deoxyglucose (**2-DG**) administration reduces mitochondrial respiration by measuring the cellular oxygen consumption rate (**OCR**) in H9 CHO cells using a *Seahorse XF24* respirometry platform. Importantly, with glucose and pyruvate supplemented in the medium to support mitochondrial respiration, 2-DG administration did not negatively affect the OCR, under both coupled and uncoupled respiration conditions ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 4A](#fig1s4){ref-type="fig"}), suggesting that glycolysis inhibition by 2-DG does not acutely impair OxPhos in CHO cells. Interestingly, oligomycin (**Oligo**) treatment immediately increased the extracellular acidification rate (**ECAR**) in H9 CHO cells, reflecting glycolysis upregulation to compensate for ATP shortage due to OxPhos inhibition, while 2-DG treatment inhibited this compensation ([Figure 1---figure supplement 4B](#fig1s4){ref-type="fig"}).

![ER ATP homeostasis is maintained by oxidative phosphorylation.\
(**A**) Confocal microscopy confirms ER localization of the ER ATP FRET reporter, ERAT in H9-D2 CHO cells. A representative confocal micrograph shows a high degree of co-localization of ERAT fluorescence in green with ER-Tracker Red, in red. (**B**) Increased F8 expression in H9-D2 CHO cells by SAHA treatment does not alter ERAT's co-localization with ER-Tracker Red. (Scale bar: 10 µm) (**C**) A cartoon model depicting the ET ATP monitoring system. Importantly, the ER is an obligate ATP consumer as there is no known ATP regeneration system inside the ER lumen. ERAT reports steady state ATP levels inside the ER, which is a dynamic balance between ATP supply and ATP consumption. (**D**) 2-DG (20 mM) has no effect on cellular respiration. Oxygen consumption rates (OCR) in H9 CHO cells were measured by an *XF-24* platform (Seahorse BioScience), using serial injections of the compounds: first PBS or 2-DG followed sequentially by 1 µM oligomycin (Oligo), 1 µM FCCP and 1 µM rotenone together with 10 µM antimycin A (Rot + AA). (**E**) The effect of OxPhos inhibitors (oligomycin, rotenone and FCCP at the indicated concentrations) on ER ATP was examined by flow cytometry at four time points as indicated. The same tubes of suspended H9 CHO cells were repeatedly sampled after OxPhos inhibition. Statistical significance values for curve comparisons by two-way ANOVA are labeled for individual inhibitors versus the 'DMSO' control group marked by an upper case 'C'. (**F**) Administration of OxPhos inhibitors for 15 min, represented by oligomycin, rotenone and FCCP, rapidly reduces ER ATP in H9 CHO cells. DMSO was included as solvent control for comparison. Statistical significance values are labeled for individual comparisons. (**G**) Administration of IAA, a glycolysis inhibitor, increases ER ATP levels (detected by flow cytometry) in H9 CHO cells. Experiments were repeated four times, and a representative result is shown. Specifically, histograms of ER ATP levels for individual cells at two IAA concentrations (50 µM and 100 µM, treated for 2 hr) are shown with the y-axis representing normalized cell counts. More than ten thousand cells were sampled for every treatment condition, as indicated on the graph. (**H**) Glucose supplementation (5 mM) to DMEM medium with only OxPhos substrates (with 1 mM sodium pyruvate supplemented) does not affect ER ATP levels. H9 CHO cells stably transfected with the ERAT reporter were incubated in the serum-free modified DMEM medium, which contains substrates (i.e. pyruvate plus L-Ala-Gln) to support only OxPhos, for 1 hr at 37°C in a cell culture incubator, before flow analysis for ER ATP status. For the '1 µM Oligo' group, oligomycin was added to cells for the last 20 min of incubation in glucose-free medium. *Two-way ANOVA* was applied for statistical analysis of geometric means of fluorescence intensity (gMFI), with significance levels expressed as: *n.s*: - not significant; \* - p≤0.05; \*\*- p≤0.01; \*\*\*- p\<0.001; \*\*\*\* - p\<0.0001. The same statistical analysis was applied in the following figures.](elife-49682-fig1){#fig1}

We subsequently tested three potent OxPhos inhibitors, oligomycin (targeting ATP synthase, also known as complex V), rotenone (targeting complex I), and FCCP (a protonophore that depolarizes the mitochondrial inner membrane to uncouple ATP synthase). All OxPhos inhibitors significantly decreased ER ATP levels immediately after administration, by analysis of ER ATP kinetics with time ([Figure 1E](#fig1){ref-type="fig"}) or by analysis at a single time point (15 min post treatment, [Figure 1F](#fig1){ref-type="fig"}). Importantly, the bio-energetic inhibitors used had no effect on ER localization of the ERAT probe, as shown by confocal microscopy in H9 CHO cells co-transfected with a cytosolic RFP-based reporter, Cyto TagRFP ([@bib23]) ([Figure 1---figure supplement 5A--F](#fig1s5){ref-type="fig"}), and was further reflected by no change in the *Pearson* correlation coefficient under these conditions ([Figure 1---figure supplement 5G](#fig1s5){ref-type="fig"}). As predicted by the chemical law of mass action, the decrease in ER ATP supply upon OxPhos inhibition should reduce ER ATP consumption. Furthermore, if we assume that the three OxPhos inhibitors do not stimulate ATP usage in the ER, the results ([Figure 1E and F](#fig1){ref-type="fig"}) indicate that the steady-state ER ATP supply is heavily dependent on OxPhos. Since the FRET signal generated from the ERAT reporter is ratiometric and does not provide a direct calibration corresponding to ATP concentration in the ER in live cells, we attempted to determine the effect of complete inhibition of cellular ATP regeneration thereby providing the lowest detection range of the ERAT reporter by treating cells for prolonged time (2 hr) with 2-DG, followed by oligomycin treatment ([Figure 1---figure supplement 6A and B](#fig1s6){ref-type="fig"}). This condition successfully identified the lower limit of the dynamic range for the ERAT reporter when the ratiometric FRET/CFP signal no longer decreases.

In contrast to OxPhos inhibition, the interpretation of effects from glycolysis inhibition is rather complicated, as there is no pure 'glycolysis inhibitor' per se, for example 2-DG application consumes cytosolic ATP and may even increase intracellular ADP levels as a substrate to boost mitochondrial ATP production through OxPhos ([Figure 1D](#fig1){ref-type="fig"}, and [Figure 1---figure supplement 4A](#fig1s4){ref-type="fig"}). With this caveat in mind, it was particularly intriguing to observe that incubation with iodoacetamide (**IAA**), an inhibitor of glyceraldehyde phosphate dehydrogenase (**GAPDH**), for 2 hr increased steady state ER ATP levels in H9 CHO cells, in a dose-dependent manner (illustrated in [Figure 1G](#fig1){ref-type="fig"}). In an effort to further measure the extent by which glycolysis-derived ATP contributes to the ER ATP pool, we found that glucose supplementation had no effect on ER ATP levels, in a defined medium with substrates supporting only OxPhos ([Figure 1H](#fig1){ref-type="fig"}), while oligomycin strongly decreased ER ATP under these conditions (p\<0.0001, with representative traces of raw FRET ratios shown in [Figure 1---figure supplement 7A](#fig1s7){ref-type="fig"}). In contrast, a third widely used glycolysis inhibitor, 3-bromopyruvate (**3-BrP**), produced a similar ATP increase in the ER, in a dose dependent manner ([Figure 1---figure supplement 7B](#fig1s7){ref-type="fig"}). At the same time, the kinetics of the ER ATP increase by 3-BrP was distinct from that by IAA, suggesting compound-specific off-target effects by the 'glycolysis inhibitors' ([Figure 1---figure supplement 7C](#fig1s7){ref-type="fig"}). Finally, the observations made in H9 CHO cells were completely reproduced in CHO cells that do not express human F8 ([@bib38]), that is oligomycin or rotenone administration reduced steady state ER ATP levels ([Figure 1---figure supplement 7D](#fig1s7){ref-type="fig"}, indicated by red and orange curves). In contrast, inhibitors of glycolysis, 2-DG or IAA, immediately increased ER ATP levels ([Figure 1---figure supplement 7D](#fig1s7){ref-type="fig"}, indicated by dark green and light green curves).

To further determine whether and to what extend the intracellular ATP regeneration requires glycolysis, total cellular ATP content was further measured by luciferase assays under the same medium conditions. As expected, glucose supplementation significantly increased cellular ATP measured ([Figure 1---figure supplement 8A](#fig1s8){ref-type="fig"}), and 2-DG decreased cellular ATP, while oligomycin only had a minor effect on cellular ATP compared to 2-DG ([Figure 1---figure supplement 8B](#fig1s8){ref-type="fig"}). These observations are consistent with the notion that CHO cells are highly dependent on glycolysis to regenerate ATP, and that the OxPhos inhibition can be readily rescued by glycolysis upregulation ([Figure 1---figure supplement 4B](#fig1s4){ref-type="fig"}). Furthermore, 2-DG immediately decreased the cytosolic ATP/ADP ratio measured by flow-cytometry using the ratiometric *PercevalHR* probe ([Figure 1---figure supplement 8C](#fig1s8){ref-type="fig"}), while OxPhos inhibition by oligomycin did not significantly alter this ratio ([Figure 1---figure supplement 8D](#fig1s8){ref-type="fig"}), as previously shown by others ([@bib13]; [@bib37]). These results provide strong evidence supporting the notion that distinct ATP supplying and regulatory mechanisms exist for subcellular compartments within a cell, as we reported ([@bib8]). During the flow cytometry data analysis, we noticed a reproducible decrease in steady-state ER ATP levels in the control group of H9-D2 CHO cells, especially after 30 mins of cell suspension (examples as shown in [Figure 1E](#fig1){ref-type="fig"}). We suspect this baseline ATP drift could be caused by the flow cytometry procedure, as extracellular matrix-attachment is crucial for optimal mitochondrial respiration ([@bib12]; [@bib29]). We acknowledge this feature as a disadvantage for flow-based ER ATP assay, and therefore have also included single-cell fluorescent microscopy recordings to complement our findings.

To conclude, OxPhos-derived ATP constitutes the major ATP supply source for the ER compartment, while it is not possible to conclude whether ER ATP depends on glycolysis-generated ATP.

ER ATP import requires a Ca^2+^ gradient across the ER membrane {#s2-2}
---------------------------------------------------------------

Protein misfolding in the ER is experimentally induced with sarco/endoplasmic reticulum Ca^2+^-ATPase (**SERCA**) inhibitors such as thapsigargin (**Tg**), which may disrupt ER ATP homeostasis. Consistent with this notion, application of the reversible SERCA inhibitor, 2,5-di-(tert-butyl)−1,4-hydroquinone (**BHQ**), caused a rapid decrease in ER ATP in rat insulinoma INS1 cells ([Figure 2A](#fig2){ref-type="fig"}). INS1 cells were selected because they secrete large amounts of another protein, proinsulin and insulin. As we reported previously ([@bib39]), due to reduced ATP levels in the ER lumen, the FRET fluorescence intensity from the ERAT probe decreased while the corresponding CFP fluorescence intensity increased simultaneously ([Figure 2B](#fig2){ref-type="fig"}). The average of FRET over CFP ratios in the population of INS1 cells decreased and reached a plateau after 10 min post BHQ perfusion ([Figure 2C](#fig2){ref-type="fig"}), and simultaneous measurement of ER Ca^2+^ by the D1ER probe ([@bib26]) in another set of INS1 cells confirmed the specific effect of BHQ on decreasing the ER Ca^2+^ concentration ([Figure 2D](#fig2){ref-type="fig"}). We observed that ER ATP levels did not completely recover after BHQ removal, while in the same time frame, the ER Ca^2+^ concentration returned to its basal level (compare [Figure 2C--2D](#fig2){ref-type="fig"}). It is particularly interesting that the ER ATP levels took longer to recover when we monitored the INS1 cells for up to 4 hr after BHQ withdrawal ([Figure 2---figure supplement 1A and B](#fig2s1){ref-type="fig"}). Furthermore, the recovered ER ATP levels in the same INS1 cells were reduced by a second BHQ stimulation, in an extent proportional to the levels of ER ATP recovery (compare [Figure 2---figure supplement 1B and C](#fig2s1){ref-type="fig"}). These phenomena suggest that the Ca^2+^-responsiveness of the putative ER ATP transporter has a 'memory' that lasts longer than the ER Ca^2+^ perturbation. In a similar manner, SERCA inhibition by Tg, an irreversible SERCA inhibitor, rapidly decreased ER ATP levels in H9 CHO cells, reflected by a decrease in the ratio of FRET-to-CFP fluorescence intensity measured by flow cytometery ([Figure 2E](#fig2){ref-type="fig"}). SERCA inhibition by Tg decreased ER ATP, independent of whether the extracellular medium contained Ca^2+^ (alpha MEM medium, 1.8 mM) ([Figure 2E](#fig2){ref-type="fig"}) or no extracellular Ca^2+^ (by 4 mM EGTA chelation, [Figure 2F](#fig2){ref-type="fig"}). A third SERCA inhibitor, cyclopiazonic acid (**CPA**), induced a similar decrease in ER ATP at a dosage fifty times higher than Tg, presumably due to its low potency for inhibiting SERCA ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). The decrease in ER ATP by Tg correlated well with ER Ca^2+^ depletion as monitored by the GEM-CEPIA1er probe ([@bib36]) ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}). Mechanistically, Tg disrupts the ER to cytosol Ca^2+^ gradient by inhibiting SERCA, a Ca^2+^ pump that shuttles 2 moles of Ca^2+^ from the cytosol into the ER lumen at the expense of 1 mole of ATP ([@bib20]). Since maintaining low cytosolic Ca^2+^ concentrations (\~100 nM under physiological conditions) also requires the action of plasma membrane Ca^2+^ pumps (**PMCA**) that consume ATP, it is possible that the decrease in ER ATP upon Tg treatment reflects mitochondrial ATP depletion due to excessive ATP usage in the cytosol. This possibility was tested by simultaneously measuring ATP levels in two sets of H9 CHO cells expressing either the ERAT probe ([Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}) or the mitochondrial ATP probe *mtAT* ([@bib13]) ([Figure 2---figure supplement 2D](#fig2s2){ref-type="fig"}). Comparison of the decrease in relative ATP levels triggered by Tg revealed that the decrease in ER ATP preceded the decrease in mitochondrial ATP ([Figure 2G](#fig2){ref-type="fig"}), refuting the notion that Tg decreases ER ATP by decreasing mitochondrial ATP. In contrast, when the cytosolic ATP/ADP status was monitored by a structurally unrelated reporter, *PercevalHR* ([@bib37]), Tg treatment attenuated the decrease in cytosolic ATP/ADP ratio in H9 CHO cells ([Figure 2H](#fig2){ref-type="fig"}). Reduced cytosolic ATP usage by SERCA or reduced ER ATP supply (see '*CaATiER model*' in [Figure 3H](#fig3){ref-type="fig"}) may explain the effect of Tg on cytosolic ATP/ADP. Tg-mediated depletion of the ER Ca^2+^ store did not appear to increase ATP usage in the ER since oligomycin treatment together with Tg reduced ER ATP only modestly, albeit significantly, compared to oligomycin alone ([Figure 2I](#fig2){ref-type="fig"}). In addition, we investigated if Ca^2+^ release mediated through IP~3~R channel opening can affect ER ATP status in single cells, using a perfusion system and FRET-based fluorescence microscopy. Extracellular ATP is a well-known physiological IP~3~-generating agonist through its engagement with purinergic receptors ubiquitously expressed on CHO cells. Indeed, exogenously supplemented ATP in the perfusion buffer noticeably decreased the ER ATP pool ([Figure 2J](#fig2){ref-type="fig"}). Furthermore, the effect of exogenous ATP was neither reversed by addition of extracellular Ca^2+^ (indicated by the blue bar in [Figure 2J](#fig2){ref-type="fig"}) or washout of the agonist, again demonstrating that Ca^2+^ mobilization lowers ER ATP levels in a sustained manner and supporting a 'memory' effect of the putative Ca^2+^ responsive ER ATP transporter. To summarize, ATP import into the ER apparently requires a Ca^2+^ gradient (Ca^2+^~ER~ \> Ca^2+^~cyto~) across the ER membrane maintained by SERCA activity.

![A Ca^2+^ gradient across the ER membrane is required to maintain ER ATP homeostasis.\
(**A**) SERCA inhibition reduces ER ATP levels in adherent INS1 cells. BHQ (15 µM) was added at 0 min as indicated. Scale bar represents 10 µm. (**B**) A representative trace of the FRET signal overlaid with the CFP fluorescence intensity is shown for illustration purposes in an adherent INS1 cell. (**C**) BHQ reduces ER ATP. Y-axis represents the ratio between FRET intensity versus CFP fluorescence intensity. The average ratio is shown in red bold solid line in the graph, with individual INS1 cells shown in gray (n = 13 cells from three experiments). (**D**) Quantification of the effect of BHQ on ER Ca^2+^ levels in individual INS1 cells. The average ratio from the Ca^2+^ reporter (D1ER) is shown by a red solid line, with individual cells shown in gray (n = 25 cells from three experiments). Notably, BHQ withdrawal at 25 min by perfusion causes Ca^2+^ refilling in the ER by SERCA re-activation. (**E**) Thapsigargin (Tg, 0.5 µM added at 0 min) reduces ER ATP significantly. Flow analysis was performed on H9 CHO cells containing the ERAT reporter and with 1.82 mM CaCl~2~ in the culture medium. Statistical significance is labeled in the figure compared to the '*DMSO*' group as control, indicated with an upper case 'C'. (**F**) In the same experiment as shown in panel (**E**), when extra-cellular Ca^2+^ in the medium was chelated by adding 4 mM EGTA, Tg shows the same effects as shown in panel (**E**) that is Tg decreases ER ATP significantly. (**G**) In response to Tg (0.25 µM final concentration, added at 0 min), the ER ATP concentration in H9 CHO decreases significantly faster than the decrease in mitochondrial ATP. ER ATP levels were measured by the ERAT probe and mitochondrial ATP was measured by the *mtAT 1.03* probe. ATP levels in the two compartments were measured simultaneously in two sets of H9 CHO cells and shared the same readout as the FRET versus CFP ratio of the probes (F~530~/F~445~). The ATP levels measured by FRET ratios were further used to calculate the Tg-induced ATP decrease standardized to the respective DMSO-treated control groups, and ATP levels are expressed as percentage of the *'DMSO'* group (% of DMSO). (**H**) Tg treatment (1 µM final concentration) increases the cytosolic ATP to ADP ratio in H9 CHO cells monitored by the *PercevalHR* reporter. Raw F~488~/F~405~ values from *PercevalHR* were corrected for the cytosolic cpYFP signal (F~488~/F~405~) in a different set of H9 CHO cells to compensate for the fluorescence change from pH change in the cytosol in response to Tg or DMSO. (**I**). In the presence of oligomycin, Tg-induced ER Ca^2+^ depletion decreases ER ATP more quickly compared to oligomycin (1 µM) alone, and the effect is dependent on the Tg concentration, that is 500 nM Tg induced a faster decrease than 100 nM Tg. (**J**) Addition of extracellular ATP (100 µM) decreases the ER ATP concentration in intact H9 CHO cells, in the presence (green line) or absence (blue line) of Ca^2+^ chelation by EGTA. In all panels, the ER ATP concentration was measured by the *ERAT4* (N7Q) probe and the y-axis indicates the FRET ratio derived by dividing fluorescence intensity at 530 nm (F~530~) by that at 445 nm (F~445~), with a 405 nm laser excitation, that is FRET ratio = F~530~/F~445~. Statistical significance is shown for the indicated concentrations, compared to the control group indicated by the superscript \"C\".](elife-49682-fig2){#fig2}

![ATP transport from mitochondria to ER is inhibited by cytosolic Ca^2+^.\
ATP stores in plasma membrane permeabilized H9 CHO cells were measured by a reporter-free method. H9 CHO cells were permeabilized with 75 µg/mL saponin in a bathing solution (referred to as 'respiration solution' hereafter). ATP production through OxPhos was supported by added pyruvate and malate (10 mM and 1 mM, respectively) as TCA substrates together with exogenous ADP (2 mM). The system was validated in two ways: First, the ATP store in the ER generated in permeabilized CHO cells was higher than that for the endogenous ATP pool detected in intact H9 CHOs (p\<0.0001 between the *'Intact'* and *'Vehicle'* group). In addition, the ER ATP store was released within 5 min after treatment with Tween-20 (0.02% vol/vol, p=0.0007 compared to *'Vehicle'* group) or Triton X-100 (0.02% vol/vol, p\<0.0001), both after 25 min of respiration (**A**). Second, inhibition of OxPhos by oligomycin (1 µM) or rotenone (1 µM) reduces the ER ATP store to baseline levels. In addition, Ca^2+^ supplemented (in the form of CaCl~2~) at 1 µM final significantly reduced the ER ATP store (**B**). (**C**). SERCA ATPase activity is blocked by pre-incubating intact H9 CHO cells with increasing concentrations of Tg (250 nM, 1 µM, and 4 µM) for 10 min. Subsequently, cells were permeabilized as described above to test if Ca^2+^ depletion affects ER ATP generated through OxPhos in permeabilized CHO cells. EGTA supplemented at 1 mM significantly increased the ER ATP store (p\<0.0001). No significant difference was observed for Tg pre-treated groups. (**D**). When ionomycin (10 µM) or Tg (1 µM) were added at the same time with PM permeabilization, EGTA significantly increased ER ATP while further Ca^2+^ add-back in the form of CaCl~2~ abolished the EGTA effect on increasing the ER ATP store. (**E**). The Ca^2+^ responsiveness of ER ATP levels was attenuated by siRNA-mediated *Slc35b1* knock-down in H9 CHO cells. Using the semi-intact cell system, CHO cells with *Slc35b1* knock-down by siRNA (24hrs post transfection) had significantly reduced ER ATP when no Ca^2+^ was present in the buffer (\*\*\*\*: p\<0.0001). With 1 µM Ca^2+^ in the buffer, ER ATP showed no difference between the control and the Slc35b1 knock-down group. (**F**). The Ca^2+^ responsiveness of ER ATP levels by SERCA inhibition was attenuated by siRNA-mediated *Slc35b1* knock-down in *HeLa* cells. *HeLa* cells expressing the ERAT4 reporter were treated with siRNA against *Slc35b1* for 48 hr before cell imaging, with si-*Slc35b1*/siRNA control = 9.5 ± 1.4% quantified by qRT-PCR (mean ± S.E.M., n = 3 samples/group). Basal ER ATP levels significantly decreased in the si-*Slc35b1* group (p\<0.001 by two-tailed t-test), compared to scrambled siRNA treated HeLa cells. Meanwhile the ER ATP decrease after BHQ addition was attenuated in the si-*Slc35b1* group. Glucose (10 mM) replacement by 2-DG (10 mM) in the end ensured cellular ATP depletion as another control. No difference was found for the two groups after 2-DG addition. (**G**) The ER ATP decrease after OxPhos inhibition (by oligomycin and rotenone) was abrogated by siRNA-mediated *Slc35b1* knock-down in HeLa cells. No difference was found for the two groups after 2-DG addition. For panels F and G, results are shown as traces representing mean ± S.E.M. (**H**) The cartoon depicts the *CaATiER* model showing mitochondrial ATP transport into the ER is antagonized by Ca^2+^ on the cytosolic side of the ER membrane.](elife-49682-fig3){#fig3}

Cytosolic Ca^2+^ inhibits ATP import into the ER {#s2-3}
------------------------------------------------

The observations presented in [Figure 2](#fig2){ref-type="fig"} indicate that a Ca^2+^ gradient is required to facilitate ATP transport into the ER lumen, reminiscent of the ATP/ADP exchange process mediated by the mitochondrial adenosine nucleotide transporters that is facilitated by a proton gradient across the mitochondrial inner membrane. However, the ER membrane is known to be quite 'leaky' to ions, with the Ca^2+^ gradient requiring maintenance by vigorous SERCA Ca^2+^ pumping into the ER lumen. As a consequence, it is theoretically difficult for the ER membrane to build a significant chemical potential to drive ATP/ADP exchange. Alternatively, as Ca^2+^ depletion from the ER lumen is inevitably coupled with a cytosolic Ca^2+^ increase in an intact cell ([@bib2]), the ER ATP transporter could respond to and be regulated by cytosolic Ca^2+^, in a process described as *CaATiER*.

To test whether ER ATP is sensitive to cytosolic Ca^2+^, we employed an independent classical ER ATP measurement for adherent H9 cells, facilitated by a standard luminescence-based ATP assay ([@bib1]; [@bib6]). The plasma membrane (**PM**) was first permeabilized with low concentrations of saponin, a cholesterol solubilizing detergent, leaving the organelle membranes intact (as these membranes contains very low levels of cholesterol) to analyze ATP transport between mitochondria and ER. ATP was generated de novo by supplying mitochondrial respiration substrates (pyruvate plus malate) together with 2 mM ADP in the respiration buffer. At the end of the incubation, the respiration buffer containing ATP generated by OxPhos was removed by aspiration (which accounted for \> 75% of the total ATP, see below). Since the ATP pool trapped in the mitochondrial matrix cannot be eliminated technically, it is possible the mitochondrial pool of ATP contributes to the 'trapped' ATP pool. However, for the permeabilized CHO cell system, we found that Ca^2+^ or Tg addition did not affect mitochondrial respiration ([Figure 3---figure supplement 1A to D](#fig3s1){ref-type="fig"}), ensuring equal ATP generation. The same results further indicate that mito-matrix ATP content does not change in response to Ca^2+^ or Tg, as the ATP synthase is extremely sensitive to the ATP-to-ADP ratio in the mitochondrial matrix. This conclusion was further demonstrated by carboxyatractyloside (an inhibitor of ANT proteins, hereafter abbreviated as '**CAt**') mediated respiration inhibition ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"} to **D,** post CAt addition). Theoretically, it is unlikely that OxPhos would respond to exogenous Ca^2+^ added in our assays, since greater than 1 µM Ca^2+^ is needed to open the MICU-regulated MCU gating of Ca^2+^ entry ([@bib40]). Furthermore, the exogenously added ADP (2 mM) should effectively drive OxPhos-generated ATP out of the mitochondrial matrix into the ER lumen or the respiration buffer. Lastly, we verified that Ca^2+^ addition did not affect total ATP generated in the supernatant ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}) calibrated by an ATP standard curve shown alongside for the absolute amount of ATP generated in our permeabilized CHO cell system ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}).

Using this system, we confirmed that only ATP trapped in the ER compartment accounts for the changes of luminescence signals above background (i.e., *ER ATP*), which was readily liberated by brief treatment with lipid-dissolving detergents ([Figure 3A](#fig3){ref-type="fig"}, p\<0.001 and\<0.0001 for Tween-20 and Triton X-100, respectively). In addition, ATP generated by OxPhos from the permeabilized cells was evidenced by the higher *ER ATP* contents trapped inside PM-permeabilized cells, compared to the endogenous ATP found inside PM-intact cells ([Figure 3A](#fig3){ref-type="fig"}, under '*Intact*' group). We also verified that ATP produced in this system was through OxPhos, as addition of OxPhos inhibitors at the beginning of incubation reduced ATP luminescence to background levels ([Figures 3B](#fig3){ref-type="fig"} and [1](#fig1){ref-type="fig"} µM *'Rotenone'* or *'Oligomycin'*). Interestingly, addition of Ca^2+^ (1 µM) significantly decreased *ER ATP* ([Figure 3B](#fig3){ref-type="fig"}, p\<0.0001 for '*0 µM Ca^2+^' vs. '1 µM Ca^2+^' bars in the 'DMSO'* group), suggesting that cytosolic Ca^2+^ inhibits ATP import from mitochondria into the ER. Alternatively, an increase in SERCA ATPase activity by increased cytosolic Ca^2+^ may reduce ATP available for the ER ATP transporter. To rule out this possibility, Tg was applied to intact H9 cells briefly before PM-permeabilization, at increasing doses from 0.25 µM to 4 µM, and the Ca^2+^ chelator EGTA was added to the respiration buffer to remove Ca^2+^ leaked from the ER into the cytosol. While 1 mM EGTA significantly increased the *ER ATP* content, addition of Tg had no effect ([Figure 3C](#fig3){ref-type="fig"}). We also tested another Ca^2+^ releasing chemical, ionomycin -- a mobile Ca^2+^ ionophore that permits Ca^2+^ transfer down the gradient, with 1 µM Tg added as a control group without pretreatment of intact cells. Again, the only effect we detected was with Ca^2+^ manipulation on the 'cytosolic' side of the ER membrane, that is EGTA chelation increased ER ATP and adding CaCl~2~ back decreased the ER ATP ([Figure 3D](#fig3){ref-type="fig"}, with free Ca^2+^ calculated to be 1 µM in presence of 1 mM EGTA).

A recent report ([@bib15]) identified SLC35B1/AXER as the putative mammalian ER ATP transporter, which enabled us to validate our model using an *Slc35b1* knock-down strategy. Consistent with the proposed role of an ER ATP/ADP translocase, knock-down of *Slc35b1* in CHO H9 cells significantly decreased the baseline ER ATP level only in assay buffer containing no Ca^2+^, but not in presence with 1 µM Ca^2+^ ([Figure 3E](#fig3){ref-type="fig"}, p\<0.0001 for '0 Ca^2+^' and non-significant for '1.0 µM Ca^2+^", respectively). The specificity of the ER ATP change was further confirmed by measuring ATP partitioned into the supernatant of the semi-intact CHO H9 system ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}), and by comparison of ER ATP as percentage of total ATP produced ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}) where it was estimated the total ATP produced is about 0.2--0.5 mM using the ATP standard ([Figure 3---figure supplement 2C](#fig3s2){ref-type="fig"}). For CHO H9 cells, *Slc35b1* knock-down efficiency was \> 50%, in the presence or absence of Tm ([Figure 3---figure supplement 2D](#fig3s2){ref-type="fig"}). Similarly, using FRET-based microscopy in intact HeLa cells, we observed that the ER ATP decrease, after an initial increase, upon BHQ treatment was attenuated in *HeLa* cells upon *Slc35b1* knock-down (by siRNA to 9.5%, compared to control siRNA treated cells) ([Figure 3F](#fig3){ref-type="fig"}). In addition, we observed a transient increase in ER ATP shortly (0--10 min) after SERCA inhibition, probably due to ER ATP usage arrest as previously reported ([@bib39]). Similarly, *Slc35b1* knock-down also abolished the ER ATP decrease as a result of OxPhos inhibition ([Figure 3G](#fig3){ref-type="fig"}, by oligo plus rotenone). A similar significant baseline ER ATP decrease after *Slc35b1* knock-down was also observed for INS1 and H9 CHO cells ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}) using microscopy, while *CaATiER* was proportionally attenuated. Furthermore, the varying *Slc35b1* knock-down efficiency may explain the difference in baseline ER ATP decrease for the three cell lines with HeLa \> H9 CHO\>INS1, as shown in ([Figure 3---figure supplements 2D](#fig3s2){ref-type="fig"} and [4](#fig3s4){ref-type="fig"}), suggesting SLC35B1 is a *bona fide* ATP/ADP translocase for the ER confirming Klein et al. Interestingly, using semi-intact H9 CHO cells, the *CaATiER* mechanism responded to Ca^2+^ concentrations ranging from 500 nM to 2 µM ([Figure 3---figure supplement 5A and B](#fig3s5){ref-type="fig"}), with ATP content in the supernatant showing the opposite changes ([Figure 3---figure supplement 5C](#fig3s5){ref-type="fig"}, calibration provided in [Figure 3---figure supplement 5D](#fig3s5){ref-type="fig"}), further demonstrating that Ca^2+^ concentrations tested in our assay affected only ATP partitioning between ER and cytosol, but not mitochondria ATP production ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Finally, the ER ATP decrease with increased Mg^2+^concentration was negligible within a physiological range from '*5 mM*' to '*10 mM*' (p=0.21 by *post-hoc* t-test), confirming the decrease in ER ATP was specific to the Ca^2+^ cation. The effect of adding CaCl~2~ back was not due to increased Cl^-^ concentration, as Cl^-^ in the form of MgCl~2~ in great excess over CaCl~2~ only had a minor effect ([Figure 3---figure supplement 6](#fig3s6){ref-type="fig"}).

In summary, based on the above results, we propose that Ca^2+^ inhibits ER ATP uptake ([Figure 3H](#fig3){ref-type="fig"}). In the *CaATiER* model, ATP from mitochondria is preferentially transported into the ER, possibly through a family of ER ATP transporter proteins represented by SLC35B1 ([@bib15]), and the cytosolic Ca^2+^ concentration within this micro-domain attenuates ATP transport through a Ca^2+^ sensing component. In addition, based on the *CaATiER* sensitivity to low µM of Ca^2+^ ([Figure 3---figure supplement 5A and B](#fig3s5){ref-type="fig"}), we predict that SLC35B1 does not encode the Ca^2+^-responsiveness considering the lack of Ca^2+^-responsiveness from 10 to 50 µM when SLC35B1 was ectopically expressed in *E Coli* ([@bib15]).

Protein misfolding in the ER increases both ER ATP dependence on OxPhos and Tg-triggered Ca^2+^ mobilization into mitochondria {#s2-4}
------------------------------------------------------------------------------------------------------------------------------

Protein misfolding in the ER is a cellular stress condition characterized by activation of the unfolded protein response (**UPR**) ([@bib32]). Although ER stress is typically induced by pharmacological means, for example with Tg to deplete ER Ca^2+^ store, or with tunicamycin (**Tm**) to inhibit N-linked glycosylation, we applied an ER stress induction model by expressing a misfolded protein in the ER lumen. ER stress was successfully induced by treating H9 CHO cells with HDAC inhibitors, such as SAHA or sodium butyrate (**NaB**), to increase F8 transcription from an HDAC-sensitive artificial promoter ([@bib9]) ([Figure 4A](#fig4){ref-type="fig"}). To better understand this proteostasis stress, we investigated if ATP supply and Ca^2+^ homeostasis are affected upon induction of F8. As ER stress is often associated with Ca^2+^ leak from the ER (in addition to those deliberately induced with Tg), we first validated this observation by investigating ER-initiated mitochondrial Ca^2+^ influx, by employing the mitochondrial matrix-localized Ca^2+^ reporter, mtGEM-GECO1 ([@bib42]) ([Figure 4B](#fig4){ref-type="fig"}). Pretreatment with 2-aminoethoxydiphenyl borate (**APB**) successfully blocked Tg-triggered mitochondrial Ca^2+^ influx, although we cannot rule out the ability of APB to block other Ca^2+^ channels ([@bib3]). As expected, the reporter promptly detected ionomycin-induced Ca^2+^ entry into the mitochondrial matrix ([Figure 4C](#fig4){ref-type="fig"}). Although ER stress induced by SAHA treatment did not alter mitochondrial matrix Ca^2+^ levels under resting conditions, Tg-triggered mitochondrial Ca^2+^ influx was significantly more prominent in ER stressed H9 cells ([Figure 4C and D](#fig4){ref-type="fig"}). From these results, we propose that ER protein misfolding stimulates ER to mitochondria Ca^2+^ transfer. The increased Ca^2+^ transfer into mitochondria was not due to an increased ER Ca^2+^ store since neither the O-cresolphthalein (**OCPC**) chromogenic method nor the ER Ca^2+^ reporter (*GEM-CEPIA1er*) revealed a significant increase in the ER Ca^2+^ content in SAHA-induced H9 CHO cells ([Figure 4E and F](#fig4){ref-type="fig"}), suggesting that the increased Ca^2+^ entry into the mitochondrial matrix under ER stress conditions is either due to enhanced Ca^2+^ mobilization from extracellular Ca^2+^ ([@bib14]; [@bib27]) or the close proximity between the ER and mitochondria under prolonged ER stress ([@bib5]). At the same time, oxygen consumption (by OCR) was not significantly different between ER stressed H9 CHO cells induced to express F8 and their un-induced counterparts ([Figure 4G](#fig4){ref-type="fig"}). Finally, when F8 expression was induced by SAHA treatment, ER ATP homeostasis became more dependent on OxPhos, as oligomycin treatment caused greater reduction in ER ATP for SAHA-treated H9 CHO cells compared to the un-induced H9 CHO cells ([Figure 4H](#fig4){ref-type="fig"}). This observation was not due to altered mitochondrial ATP supply ([Figure 4G](#fig4){ref-type="fig"}) as mitochondrial ATP levels were not affected upon induction of F8 expression ([Figure 4---figure supplement 1A and B](#fig4s1){ref-type="fig"}). Lastly, we verified the oligomycin-induced decrease in ER ATP in adherent single H9 CHO cells using FRET-based fluorescence microscopy ([Figure 4I& J](#fig4){ref-type="fig"}). Consistent with the ER ATP status measured by flow cytometry, the ER ATP decrease in response to complete OxPhos inhibition was significantly more pronounced in SAHA-induced ER stressed H9 CHO cells than in vehicle-treated CHO cells (quantified by maximal ER ATP reduction, [Figure 4K](#fig4){ref-type="fig"}, p\<0.05). Since ATP dependence on OxPhos suggested that ER stress could have caused an 'anti-Warburg effect' by inhibiting ATP production from glycolysis, we further tested if the cytosolic bioenergetic dependence on OxPhos was similarly affected by ER stress induced by Tm. Similar to the ER compartment, the cytosolic ATP/ADP ratio decreased more quickly upon OxPhos inhibition ([Figure 4---figure supplement 1C and D](#fig4s1){ref-type="fig"}), while no obvious difference was detected for the mitochondrial matrix ATP pool. Fully supporting the '*anti-Warburg effect*', ER stressed H9 CHO cells had significantly reduced glucose uptake independently of the F8 inducer, measured by 2-NBDG fluorescence assay ([Figure 4---figure supplement 2A and B](#fig4s2){ref-type="fig"}). Notably, only H9 CHO but not 10A1 CHO showed a significant reduction in glucose uptake in response to SAHA, as the latter cells lack the HDAC inhibitor responsiveness and do not exhibit ER stress, as previously demonstrated ([@bib9]). To summarize, ER stress induced by a misfolded ER luminal protein causes metabolic changes, characterized by increased Ca^2+^ exchange between ER and mitochondria ([@bib2]; [@bib14]), increased dependence on ATP produced by OxPhos and by decreased cellular glucose uptake.

![Protein misfolding in the ER increases ER ATP dependence on OxPhos and increases ER to mitochondrial Ca^2+^ trafficking.\
(**A**) When treated with HDAC inhibitors, such as SAHA or sodium butyrate (**NaB**), F8 transcription is induced in H9 CHO cells accompanied by UPR activation. SAHA was tested at increasing concentrations, at 50 nM, 200 nM, 1 µM, 5 µM and 20 µM, as indicated by pink arrow heads. NaB was used at 5 mM. *'D'* indicates the same volume of DMSO as a vehicle control. The last two lanes received 10 µg/mL tunicamycin (Tm) as positive controls for ER stress. Treatment times are labeled on the top of the Western blot panels. (**B**). Representative histograms of mitochondrial Ca^2+^ influx, reported by the *mtGEM-GECO1* Ca^2+^ probe, were overlaid for visual comparison. For the particular *'Tg'* trace, H9 CHO cells were treated with 5 µM Tg for 30 min; and for the *'APB+Tg'* trace, the same cells received 50 µM of APB before Tg stimulation. (**C**) While the mitochondrial Ca^2+^ concentrations show no difference at the basal level, Tg (5 µM)-triggered a higher mitochondrial Ca^2+^ spike in H9 cells with induced F8 expression (5 µM SAHA x 21 hr). An independent group of un-induced H9 CHO cells received ionomycin (10 µM) as a positive control. (**D**) Tg (5 µM)-triggered mitochondrial Ca^2+^ spikes in un-induced H9 and induced H9 cells for F8 expression are shown by bar graphs, with average signal strengths represented as percent of baseline (without Tg treatment) from four consecutive readings within 45 min. The Ca^2+^ signal from the mitochondrial matrix in ER stressed H9 cells (5 µM SAHA x 21 hr) was significantly increased compared to its vehicle-treated control group (*'SAHA'* versus *'DMSO'*, p\<0.05), both of which were partially blocked by 40 µM APB. (**E**) Intracellular Ca^2+^ content was not significantly changed in H9 cells with F8 expression induced by SAHA, compared to control H9 cells as measured by the OCPC chromogenic method. (**F**) ER Ca^2+^ levels in H9 CHO cells were monitored by the *GEM-CEPIA1er* probe through flow cytometry-based ratiometric analysis. SAHA (5 µM for 18 hr) induces ER stress by increasing F8 expression in the ER, and Tm (100 ng/mL for 18 hr) induces ER stress by blocking N-linked glycosylation on proteins translocated into the ER. ER Ca^2+^ levels in H9 CHO cells remained unchanged compared to the DMSO-treated control cells. (**G**) In H9 CHO cells with induced F8 expression, the OCR was slightly increased but not significantly different, as measured by the Seahorse flux assay (n = 6 wells/group). (**H**). Blockade of ATP production through OxPhos by oligomycin depletes ATP more quickly in induced H9 cells compared to un-induced H9 CHO cells, when standardized to DMSO-treated cells. (**I**) and (**J**) Traces for ER ATP in individual H9 CHO cells are shown in response to oligomycin administration (10 µM, indicated by arrow heads). In panel (**I**), cells were treated 18 hr with DMSO, a vehicle control for SAHA; In panel (**J**), cells were treated 18 hr with 5 µM SAHA. (**K**) Similar to measurements made by flow-cytometry (panel **H**), oligomycin caused significantly greater maximal ER ATP reduction (\*, p\<0.05 by two-tailed *Student's* t-test) in SAHA-induced H9 cells compared to '*Vehicle*' treated H9 CHO cells.](elife-49682-fig4){#fig4}

Discussion {#s3}
==========

ATP drives most metabolic reactions inside the cell, and its transport mechanism between mitochondria and cytosol is well characterized. In contrast, little is known about how ATP is transported into the ER, an obligate ATP consuming organelle with no known ATP regeneration machinery ([@bib4]; [@bib10]).

Mitochondria supply ATP to the ER and cellular OxPhos is enhanced by ER ATP usage {#s3-1}
---------------------------------------------------------------------------------

By using a series of ATP and ATP/ADP ratio reporters to monitor real-time ATP changes in sub-cellular compartments and by complementary direct measurements of ER ATP, we observed that ATP in the ER is mainly supplied from mitochondria and that ATP homeostasis in the ER is maintained through a cytosolic Ca^2+^-antagonized ATP transport mechanism on the ER membrane ([Figure 3H](#fig3){ref-type="fig"}). It was surprising that the ATP level in the ER is insensitive to transient glucose deprivation and inhibition of glycolysis, which causes an immediate reduction in cytosolic ATP. This result is consistent with our conclusion that OxPhos supplies ATP to the ER and a highly efficient ATP transport mechanism exists from mitochondria to ER. Considering the close proximity between the ER and mitochondria ([@bib33]), it is possible that ATP exiting mitochondria immediately traffics through the ER ATP transporter(s), whereas ATP produced by glycolysis is spatially more distant to be efficiently captured by the ER. In addition, supporting the symbiotic evolutionary hypothesis of mitochondria, our findings suggest that the ER takes special advantage of ATP-producing mitochondria to fulfill the energetic demands for protein folding, trafficking and secretion ([@bib33]), reflected by the exquisite sensitivity of the ER ATP levels to OxPhos inhibition. Therefore, an intimate cross-talk between ER protein misfolding and mitochondrial function could have evolved as a bioenergetic advantage for eukaryotes to develop into multi-cellular organisms, in which cell-to-cell communications is necessitated by paracrine and endocrine signals. Based on our findings, we propose that ATP usage in the ER is a key signaling event that controls mitochondrial bioenergetics, in addition to the signaling mediated by Ca^2+^ and reactive oxygen species (**ROS**) ([@bib14]).

Cytosolic Ca^2+^ attenuates ATP import into the ER {#s3-2}
--------------------------------------------------

One of our most important observations is that a Ca^2+^ gradient across the ER membrane is necessary for ATP transport into the ER. Specifically, to demonstrate that cytosolic Ca^2+^ inhibits ATP import, we applied an artificial PM-permeabilized cell system, by forcing mitochondrial respiration to supply ATP, for the reason that 1) the Ca^2+^ concentration can be conveniently manipulated in this semi-intact experimental system; 2) the ATP supply is no longer limited by ADP availability which is considered a rate-limiting factor in vivo. Our *CaATiER* model was further validated by knock-down of ER ATP transporter expression, encoded by the *Slc35b1* gene ([@bib15]). Notably, the SERCA inhibitor, BHQ, induced a phenomenal ER ATP decrease, which was greatly attenuated in HeLa cells with *Slc35b1* knock-down ([Figure 3F](#fig3){ref-type="fig"}), indicating that the observed ER ATP drop is mediated by reduced ATP import into the ER. The results confirm that 1) ATP is not freely permeable to the ER membrane, and 2) The ATP transport mechanism on the ER membrane (through SLC35B1/AXER) is exquisitely sensitive to the cytosolic Ca^2+^ concentration. Although it was suggested that the immediate Ca^2+^ mediated increase in ER ATP requires AMPK activity ([@bib39]), whether AMPK is involved in *CaATiER* in intact cells is an open question. Our findings lead us to propose that cytosolic Ca^2+^ inhibits ATP import into the ER, indicating that a Ca^2+^ responsive element faces the cytosolic surface ([Figure 3H](#fig3){ref-type="fig"}), analogous to the mitochondrial Ca^2+^ uniporter (**MCU**) gating system ([@bib19]; [@bib40]).

Physiological processes require exquisitely meticulous and tight regulation of ATP, that is cytosolic ATP abundance is sensed and converted into a Ca^2+^ chemical gradient by the coupling function of SERCA where excess cytosolic ATP will only be delivered to the ER when cytosolic Ca^2+^is at physiological levels (\<500 nM). In summary, we propose that increased cytosolic Ca^2+^ reduces ER ATP usage to conserve ATP for cytosolic functions. Evolutionarily, the risk of ER stress resulting from a transient ATP shortage is accommodated by bountiful ER chaperones, such as GRP78/BiP and GRP94, for which peptide binding activities are regulated by ATP ([@bib10]; [@bib28]; [@bib41]), and Ca^2+^ responsive chaperones ([@bib2]), such as calnexin and calreticulin ([@bib16]). Previous observations associating ER Ca^2+^ release with a transient ER ATP increase ([@bib39]) (and repeated in [Figure 3F](#fig3){ref-type="fig"}) could reflect a temporary reduction in ER ATP consumption, rather than reflecting the luminal Ca^2+^ sensitivity of the ER ATP import machinery.

ER protein misfolding increases the ER bioenergetic requirement for ATP from OxPhos {#s3-3}
-----------------------------------------------------------------------------------

It has long been postulated that Ca^2+^ micro-domains formed by ER-mitochondrial contacts could potentially stimulate mitochondrial respiration to encourage efficient ATP production, especially under conditions of ER stress ([@bib5]; [@bib14]). The structural proximity is maintained by the ER-mitochondria tethering molecules, such as Mitofusin 2 ([@bib25]; [@bib31]), while the functional cooperation through adenosine nucleotide exchange between the ER and mitochondria has not been directly proven. Uniquely here, we demonstrate that the ER preferentially depends on ATP produced from OxPhos, which was further confirmed by our observation that ER protein misfolding in H9 CHO cells causes an '*anti-Warburg*' effect. Whether this observation can be extrapolated to interpret cancer cell metabolism warrants further investigation. While confirming the intimate functional cooperation of ER and mitochondria through exchange of adenosine nucleotides, our findings demonstrate that increased Ca^2+^ on the cytosolic surface of the ER membrane inhibits ER ATP import and predict that the Ca^2+^ exchange domain is not compatible with the ATP exchange domain between mitochondria and the ER, suggesting the existence of either A) Two categories of contact domains between the organelles, or B) A domain that operates in two distinct modes (Ca^2+^ exchange mode versus ATP exchange mode), which are temporally separated.

ER stress caused by protein misfolding can cause cell death under pathological conditions. ER stress-induced cell death is associated with increased oxidative stress ([@bib22]; [@bib21]). It is plausible that AMPK activation as a consequence of Ca^2+^ efflux from the ER ([@bib15]) can lead to compensatory mitochondrial ATP production in an attempt to resolve ER stress by supplying more ATP to the ER. OxPhos up-regulation as a feedback mechanism to increase ER ATP consumption could contribute to mitochondrial ROS generation, although altered mitochondrial function was not detected in our study ([Figure 4G](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A and B](#fig4s1){ref-type="fig"}). Conversely, dysfunctional mitochondria can elevate ROS production by the ER ([@bib24]). In our CHO cell model system, when Tg was applied to release ER Ca^2+^, the Ca^2+^ influx into the mitochondrial matrix was significantly elevated in ER-stressed CHO cells, which could reflect the closer proximity between ER and mitochondria to ensure sufficient ATP uptake into the ER ([@bib14]). In vivo, a similar process of IP~3~R-mediated Ca^2+^ release in response to IP~3~ generated by repeated plasma membrane receptor engagement may exacerbate ROS production as a result of mitochondrial Ca^2+^ overload ([@bib17]).

To conclude, our results expand our knowledge of cellular bioenergetics by demonstrating that a highly efficient ATP supply mechanism exists between mitochondria and ER that is antagonized by cytosolic Ca^2+^. Our findings should stimulate research to identify and to elucidate the Ca^2+^-sensing molecular mechanism associated with the ER ATP transporter molecule(s).

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                      Designation                                                                     Source or reference                                                             Identifiers                                      Additional\
  (species) or\                                                                                                                                                                                                                                       information
  resource                                                                                                                                                                                                                                            
  ---------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------ --------------------------------------------
  Cell line (*Cricetulus griseus*)   CHO DUK cell line                                                               Dr. Lawrence Chasin at Columbia University, USA., Personal gift                 N/A                                              Confirmed by karyotyping

  Cell line (*Cricetulus griseus*)   CHO H9 cell line                                                                Made in Kaufman Lab                                                             N/A                                              Confirmed by karyotyping, further by F8 WB

  Cell line (*Rattus norvegicus*)    INS1 cell line                                                                  Gift from Dr. Christopher B. Newgard,\                                          N/A                                              Confirmed by WB and electrophysiology
                                                                                                                     Duke University, USA                                                                                                             

  Cell line (*Homo-sapiens)*         HeLa S3 cell line                                                               ATCC                                                                            \# CCl-2.2                                       Assurance by ATCC

  Antibody                           anti-F8, IgG1\                                                                  Green Mountain Antibodies                                                       GMA 012                                          WB: 1:1000
                                     (Mouse monoclonal)                                                                                                                                                                                               

  Antibody                           anti-BiP, IgG\                                                                  Cell Signaling Technology                                                       CST 3177                                         WB: 1:1000
                                     (Rabbit monoclonal)                                                                                                                                                                                              

  Antibody                           anti-CHOP, IgG\                                                                 Santa Cruz Biotechnology                                                        SC 575                                           WB: 1:1000
                                     (Rabbit polyclonal)                                                                                                                                                                                              

  Antibody                           phospho-eIF2α (Ser51), IgG\                                                     Cell Signaling Technology                                                       CST 3597S                                        WB: 1:1000
                                     (Rabbit monoclonal)                                                                                                                                                                                              

  Antibody                           anti-phospho-p70S6K (Thr421/Ser424), IgG (Rabbit polyclonal)                    Cell Signaling Technology                                                       CST 9204                                         WB: 1:1000

  Antibody                           anti-VINCULIN, IgG1 (Mouse monoclonal)                                          Sigma                                                                           V9131                                            WB: 1:1000

  Recombinant DNA reagent            *mtAT 1.03, plasmid*                                                            Dr. Hiromi Imamura at Kyoto University, personal gift                           N/A                                              ATP level

  Recombinant DNA reagent            *ERAT 4.01 N7Q, plasmid*                                                        NGFI, Austria                                                                   N/A                                              ATP level

  Recombinant DNA reagent            pTagRFP-C*, plasmid*                                                            *Evrogen*                                                                       \#FP141                                          Cytosolic location

  Recombinant DNA reagent            GW1-*Perceval HR, plasmid*                                                      Addgene                                                                         \#49082                                          ATP/ADP ratio

  Recombinant DNA reagent            *D1ER, plasmid*                                                                 Dr. Demaurex at Universitè de Genève, Switzerland, personal gift                N/A                                              Ca^2+^ level

  Recombinant DNA reagent            pCIS *GEM-CEPIA1er, plasmid*                                                    Addgene                                                                         \#58217                                          Ca^2+^ level

  Recombinant DNA reagent            CMV-mito-*mtGEM-GECO1, plasmid*                                                 Addgene                                                                         \#32461                                          Ca^2+^ level

  Recombinant DNA reagent            *ER-RFP, plasmid*                                                               Addgene                                                                         \#62236                                          ER localization

  Recombinant DNA reagent            *cpYFP, plasmid*                                                                Dr. Yi Yang at East China University of Science and Technology, personal gift   N/A                                              pH level

  Sequence-based reagent             Puromycin resistant gene, 5' primer 5'-ACAAATGTGGTAAAATCGATAAGGATCCG-3';        Integrated DNA Technologies                                                     N/A                                              PCR primer

  Sequence-based reagent             Puromycin resistant gene, 3' primer 5'-GAGCTGACTGGGTTGAAGGCT-CTCAAGGGC-3'       Integrated DNA Technologies                                                     N/A                                              PCR primer

  Sequence-based reagent             *siRNA Slc35b1*-\                                                               Microsynth AG, Balgach, Switzerland                                             N/A                                              siRNA
                                     5'-GAG ACU ACC UCC ACA UCA A dTdT-3' (targeting 3'-UTR of human gene)                                                                                                                                            

  Sequence-based reagent             *siRNA* scrambled-\                                                             Microsynth AG, Balgach, Switzerland                                             N/A                                              siRNA
                                     5\'-AGG UAG UGU AAU CGC CUU G dTdT-3\' (control for human*Slc35b1* knockdown)                                                                                                                                    

  Sequence-based reagent             *siRNA targeting mouse Slc35b1 sequence --*\                                    Qiagen                                                                          Mm_Ugalt2_1, SI01461523                          siRNA
                                     5'-CCACATGATGTTGAACATCAA-3'                                                                                                                                                                                      

  Sequence-based reagent             *siRNA targeting mouse Slc35b1 sequence --*\                                    Qiagen                                                                          Mm_Ugalt2_2, SI01461530                          siRNA
                                     5'- AAGAAGGTGGTTGGAATAGAA-3'                                                                                                                                                                                     

  Sequence-based reagent             *siRNA targeting mouse Slc35b1 sequence --*\                                    Qiagen                                                                          Mm_Ugalt2_4, SI01461544                          siRNA
                                     5'-TCGGTAAATCCTGCAAGCCAA-3'                                                                                                                                                                                      

  Sequence-based reagent             *siRNA scrambled --*\                                                           Qiagen                                                                          Allstars Negative Control siRNA, Cat \#1027280   siRNA
                                     *Sequence proprietary*                                                                                                                                                                                           

  Commercial assay or kit            TransFast Transfection Reagent                                                  Promega Corporation, Madison, USA                                               \# E2431                                         

  Commercial assay or kit            FuGENE 6\                                                                       Promega                                                                         \# E2693                                         
                                     Transfection Reagent                                                                                                                                                                                             

  Commercial assay or kit            Calcium Assay Kit                                                               Adipogen Corp.                                                                  \# JAI-CCA-030                                   

  Commercial assay or kit            XF24 extracellular flux assay kit                                               Seahorse BioSciences                                                            \# 100850--001                                   

  Commercial assay or kit            Ingenio Electroporation solution                                                Mirus Bio LLC                                                                   \# MIR 20114                                     

  Commercial assay or kit            ATPLite kit                                                                     Perkin Elmer                                                                    \# 6016943                                       

  Commercial assay or kit            MycoAlert plus Mycoplasma Detection kit                                         Lonza                                                                           \#LT07-703                                       

  Chemical compound, drug            2-Deoxy-D-glucose                                                               Chem-Impex Int'l, INC                                                           \# 21916                                         

  Chemical compound, drug            2,5-Di-(t-butyl)−1,4-hydroquinone (BHQ)                                         SIGMA                                                                           \# 112976--25G                                   

  Chemical compound, drug            2-NBDG                                                                          Cayman Chemical                                                                 \# 11046                                         

  Chemical compound, drug            3-Bromopyruvate                                                                 Aldrich Chemistry                                                               \# 16490--10G                                    

  Chemical compound, drug            Cyclopiazonic acid                                                              Alfa Aesar                                                                      \# J61594                                        

  Chemical compound, drug            FCCP                                                                            SIGMA                                                                           \# C2920-10MG                                    

  Chemical compound, drug            Iodoacetamide                                                                   SIGMA                                                                           \# I1149-5G                                      

  Chemical compound, drug            Ionomycin                                                                       AdipoGen                                                                        \# AG-CN2-0418                                   

  Chemical compound, drug            Oligomycin A                                                                    Alfa Aesar                                                                      \# J60211                                        

  Chemical compound, drug            Rotenone                                                                        SIGMA                                                                           \# R-8875--1G                                    

  Chemical compound, drug            SAHA                                                                            Tocris                                                                          \# 4652                                          

  Chemical compound, drug            Thapsigargin                                                                    SIGMA                                                                           \# T9033-5MG                                     

  Chemical compound, drug            Tunicamycin                                                                     Santa Cruz Biotechnology                                                        \# sc-3506                                       

  Software, algorithm                GraphPad Prism 7                                                                GraphPad Software                                                               Version: 7                                       

  Software, algorithm                FlowJo 10                                                                       FlowJo LLC                                                                      Version: 10.2                                    

  Software, algorithm                Adobe Illustrator                                                               Adobe                                                                           Version: CS 5.1                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Construction and validation of H9 CHO cell line {#s4-1}
-----------------------------------------------

The F8 inducible H9 CHO cell system was described previously ([@bib9]; [@bib21]). Expression of F8 was confirmed by Western blot using specific monoclonal antibodies -- anti-F8 (Green Mountain Antibodies, GMA 012, murine IgG1), anti-BiP (Cell Signaling Technology, CST 3177, rabbit IgG), anti-CHOP (Santa Cruz Biotechnology, SC 575, rabbit IgG), anti-phospho-eIF2α at Ser51 (Cell Signaling Technology, CST 3597S, rabbit IgG), anti-phospho-p70S6K at Thr421/Ser424 (Cell Signaling Technology, CST 9204, rabbit IgG), and anti-VINCULIN (Sigma, V 9131, murine IgG1).

Construction of novel reporter cell lines {#s4-2}
-----------------------------------------

CHO cells were transfected with the reporter plasmids using the Amaxa Nucleofector II electroporation system in the Mirus Ingenio solution (Cat \# MIR 20114). For reporter plasmids with G418 resistance, a brief G418 selection (0.5 mg/mL) was applied on transfected CHO cells for one week. The population of surviving cells was allowed to recover for two weeks before they were used for ER ATP analysis by flow cytometry. For reporter plasmids without a mammalian selection marker, a puromycin resistance cassette (\~1.23 kb, amplified from plasmid pGL4.21) was co-transfected using the *Amaxa Nucleofector II* electroporation system in the *Mirus Ingenio* solution. After a brief puromycin selection (5 µg/mL for five days), cells were allowed to recover for two weeks before they were used for fluorescence ratio analysis by flow cytometry.

More specifically, plasmids encoding the *ER-RFP* reporter (ER-mRFP, \#62236), the *PercevalHR* reporter (*GW1-PercevalHR,* \#49082), the *CEPIA1er* reporter (p*CIS GEM-CEPIA1er,* \#58217) and the *mtGEM-GECO1* reporter (*CMV-mito-GEM-GECO1*, \#32461) were purchased from *Addgene*. The plasmid encoding the *ERAT4.01^N7Q^* reporter was purchased from *Next Generation Fluorescence Imaging* Company (NGFI, Austria). The plasmid encoding the *TagRFP* reporter was purchased from *Evrogen* (pTagRFP-C, \#FP141). The plasmid encoding the *mtAT1.03* reporter was a kind gift from Dr. Hiromi Imamura at Kyoto University. The plasmid encoding the *cpYFP* reporter was a kind gift from Dr. Yi Yang at the East China University of Science and Technology, and the plasmid encoding the *D1ER* reporter was a kind gift from Dr. Demaurex at Universitè de Genève, Switzerland. Refer to [Supplementary file 1](#supp1){ref-type="supplementary-material"} for a summary of the reporter proteins' subcellular localization and their reporting specificity.

Confocal microscopy {#s4-3}
-------------------

For live cell imaging of subcellular localization of ERAT in H9 CHO, targeting to the ER was validated using an array confocal laser scanning microscope (ACLSM) built on a fully automated inverse microscope (Axio Observer.Z1, Zeiss, Göttingen, Germany), using a 100x objective (Plan-Fluor 100 x/1.45 oil, Zeiss). CHO cells expressing ERAT were additionally transfected with ER-RFP ([@bib35]), and either treated with vehicle (DMSO) or 5 µM SAHA for 18 hr. Live cells were excited using diode lasers (Visitron Systems, Puchheim, Germany): CFP of ERAT was excited at 445 nm (50 mW), RFP of ER-RFP was excited at 561 nm (50 mW). Emissions were collected using the emission filters ET480/40 for CFP and E570LPv2 for RFP, respectively (Chroma Technologies Corporation, VT, USA). All images were captured at a binning of 2 using a photometrics CCD camera (CoolSnap HQ2, Photometrics, Arizona, USA), and images were processed using ImageJ software.

For fixed H9 CHO cells after immunostaining with anti-PDIA6 antibody, confocal images of stably transfected CHO cells were taken on an Olympus Fluoview 1000 platform, using the following excitation and emission filters - for DAPI, Ex 405 nm/Em 461 nm; for ERAT protein, Ex 488 nm/Em 519 nm; for PDIA6 (immuno-detected by Alexa-594 conjugated secondary antibody), Ex 561 nm/Em 618 nm. Objective lenses of 60x (PlanApo N, N.A = 1.42 oil) and 100x (UPlanSApo N.A. = 1.40 oil) were used.

Quantification of ER ATP and Ca^2+^ levels by fluorescence ratiometry analysis in live cells {#s4-4}
--------------------------------------------------------------------------------------------

Analyses of ER ATP levels in INS-1 832/13 (INS-1) cells were facilitated with the ERAT 4.01 reporter introduced by conventional lipofectamine-transfection. Imaging of ER Ca^2+^ levels was performed using the ER targeted Ca^2+^ reporter D1ER. Prior to measurements, cells were equilibrated for 30 min using storage buffer composed of (mM): 138 NaCl, 5 KCl, 2 CaCl~2~, 1 MgCl~2~, 10 HEPES, 2.6 NaHCO~3~, 0.44 KH~2~PO~4~, 0.34 Na~2~HPO~4~, 10 D-glucose, 2 L-glutamine, with the following supplements (vol/vol): 0.1% vitamins, 0.2% essential amino acids, and 1% penicillin--streptomycin, pH adjusted to 7.4 with NaOH. The experimental buffer used for the perfusion of the cells during the fluorescence microscopic experiments was composed of (mM) 138 NaCl, 5 KCl, 1 MgCl~2~, 10 HEPES, 10 glucose, either with 2 CaCl~2~ or 0.1 EGTA with no added CaCl~2~, pH adjusted to 7.4 with NaOH. During the experiment, buffers were exchanged using a flow chamber, connected to a gravity-based perfusion system (NGFI, Graz, Austria) and a vacuum pump (Chemistry diaphragm pump ME 1 c, Vacuubrand, Wertheim, Germany).

CHO cells stably expressing the ERAT4.01^N7Q^ reporter were directly analyzed after removing the alpha MEM medium. Cells were cultured and analyzed in µ-slide four wells (ibidi GmbH, Planegg, Germany). For the experiments, alpha MEM was removed and replaced by experimental buffer composed of (mM): 138 NaCl, 5 KCl, 1 MgCl~2~, 10 HEPES, 10 glucose, 2 CaCl~2~, 2 pyruvate and four glutamate, pH adjusted to 7.4 using NaOH.

All fluorescence microscopic experiments were performed using an iMic inverted and advanced fluorescent Microscope with a 40x magnification objective (alpha Plan Fluor × 40, Zeiss, Göttingen, Germany) and a motorized sample stage (TILL Photonics, Graefling, Germany). Excitation was performed at 430 nm (Polychrome V, Till Photonics), emissions were collected simultaneously at 475 nm for CFP and 525 nm for YFP, respectively, using a beam splitter. Images were captured using a binning of 2 with a CCD camera (Allied Vision Technologies, Stadtroda, Germany) and analysis was performed using Live Acquisition software (TILL Photonics). Representative ratio images were created using MetaMorph microscopy automation and image analysis software (Molecular Devices, Sunnyvale, CA, USA).

ER and mitochondrial ATP level analysis by flow cytometry {#s4-5}
---------------------------------------------------------

For FRET-based ATP determination, a Novocyte 3000 flow cytometer (ACEA BioSciences) was used to record ERAT fluorescence at channels with Ex/Em filters set as following: 1). 405 nm/ 445 (band width: 45) nm; 2). 405 nm/ 530 (band width: 30) nm. ER and mitochondrial ATP levels for individual cells were defined as the ratio of fluorescence intensity of channel 2 (Ex/Em: 405/530) divided by that of channel 1 (Ex/Em: 405/445), similar to parameters used previously ([@bib13]; [@bib39]). In addition, fluorescence intensities of the following channels were recorded for probe abundance quantification, and for data validity verification: 1) 405 nm/ 572 (band width: 28) nm; 2) 488 nm/ 530 (band width: 30) nm; and 3) 488 nm/ 572 (band width: 28) nm.

Cytosolic ATP/ADP ratio analysis by flow cytometry {#s4-6}
--------------------------------------------------

For cytosolic ATP/ADP ratio determination in H9 CHO cells expressing the *PercevalHR* reporter, an LSR Fortessa flow cytometer (BD Biosciences) or a Novocyte 3000 flow cytometer (ACEA BioSciences) were used to record fluorescence intensity of channels with Ex/Em as following: 1) 405 nm/ 525 nm (band width: 50 nm); and 2) 488 nm/ 510 nm (band width: 25 nm). The cytosolic ATP/ADP ratio for individual cells is defined as the ratio of fluorescence intensity of channel 2 (Ex/Em - 488/510) divided by that of channel 1 (Ex/Em - 405/525), similar to previously described ([@bib13]; [@bib37]). In addition, as fluorescence signals from the *PERCEVAL-HR* protein are known to be sensitive to cytosolic pH changes upon compound addition, the ratiometric F~525~/F~510~ was corrected by simultaneously measuring pH changes using the cpYFP overexpressing H9 CHO cells using a first-order correction ([@bib43]).

Mitochondria Ca^2+^ influx analysis by flow cytometry {#s4-7}
-----------------------------------------------------

CHO cells were transfected with the *mtGEM-GECO1* plasmid as described above, and after brief G418 selection for a week, cells were allowed to recover for two weeks before they were used for mitochondria Ca^2+^ influx analysis by flow cytometry using a Novocyte 3000 flow cytometer. For mitochondrial matrix Ca^2+^ level, a ratiometric measurement was derived using fluorescence intensity of channel one with Ex/Em of 405 nm/ 445 nm (band width: 45 nm) divided by that of channel two with Ex/Em of 405/530 nm (band width: 30 nm), similar to a procedure previously described ([@bib42]).

ER luminal Ca^2+^ analysis by flow cytometry {#s4-8}
--------------------------------------------

CHO cells were transfected with the *GEM-CEPIA1er* plasmid as described above, and after brief puromycin selection (5 µg/mL for five days), fifteen percent of the transfected cells were positive for the *CEPIA1er* reporter as quantified by flow cytometry analysis. Cells were allowed to recover for two weeks before they were used for ER lumen Ca^2+^ analysis by flow cytometry facilitated by a Novocyte 3000 flow cytometer. For Ca^2+^ determination, a ratiometric measurement was derived using fluorescence intensity of channel one with Ex/Em of 405 nm/ 445 nm (band width: 45 nm) divided by that of channel two with Ex/Em of 405/530 nm (band width: 30 nm), similar to a procedure previously described ([@bib36]).

Flow data analysis by FlowJo software {#s4-9}
-------------------------------------

Flow cytometry data recorded by cytometers were saved as FCS 3.1 files and analyzed by FlowJO software (Version: 10.2, FlowJo LLC) on a Mac platform. Briefly, cells were first gated by forward light scatter and side light scatter (FSC-H and SSC-H, respectively) to ensure that only fluorescence signals from live singlet cells were analyzed. Within the population, subsets of reporter-positive and reporter-negative populations were further differentiated by plotting the fluorescence intensity at designated channels. A ratio parameter was further defined using the FlowJo's '*Derived Parameters*' function, as defined above for each reporter. Normality of the derived parameter was subsequently checked by plotting a histogram for every ratiometric parameter. Furthermore, the geometric mean of fluorescence intensity (gMFI) was applied for population statistics analysis, as ratiometric parameters usually follow a log-normal distribution. Typically, statistics from a reporter positive population of more than 3000 singlet cells at any given time point were used to ensue data reproducibility.

Effect of pharmacological reagents on ER and mitochondria ATP levels {#s4-10}
--------------------------------------------------------------------

Mito-toxins and glycolysis inhibitors were diluted to 100x stock concentrations in DMSO or PBS. All chemical inhibitors were purchased from Sigma or Thermo Fisher unless indicated otherwise. On the day of flow analysis, 10 µL of compounds were aliquoted into Falcon polypropylene tubes (Corning Cat \# 352063) before 1 mL of cell suspension was added to make the final concentration. In any particular experiment where multiple compounds were used for compound effects comparison, for example [Figure 1E and F](#fig1){ref-type="fig"}, all compounds were pre-pipetted into the Falcon tubes before cell addition. To ensure population homogeneity, cells from the same tubes were aliquoted to the compound-containing tubes or to the vehicle-containing tubes for data collection.

Furthermore, based on the observation that H9 cells with high ERAT4 reporter expression have improved data sphericity for FRET ratio ([Figure 1---figure supplement 3A&B](#fig1s3){ref-type="fig"} *versus* **C and D**), we generated a single H9-D2 CHO cell clone with unanimous high levels of ERAT4 expression, by seeding single cells into multiple 96-well cell culture plates, followed by manual selection of clones with high YFP fluorescence intensities. Data sphericity for FRET ratio of H9-D2 CHO cell was further confirmed by flow cytometry-based FRET signal analysis, as described above.

Cellular metabolic flux analysis by Seahorse XF24 platform {#s4-11}
----------------------------------------------------------

Cellular oxygen consumption rate (**OCR**) and extracellular acidification rate (**ECAR**) were analyzed on a Seahorse XF24 analyzer (*Seahorse BioSciences*). H9 CHO or CHO-DUK cells were seeded onto a XF24 cell culture microplate 4--5 hr before the assay to allow cell attachment to the plate. OCR and ECAR were measured following XF24's standard operating procedures as per manufacturer's manual, facilitated by a XF24 extracellular flux assay kit (*Seahorse BioSciences*, Part \# 100850--001). In addition, to measure OCR and ECAR in F8-induced H9 CHO cells, the subject CHO cells were first induced by 5 µM SAHA for 21 hr in a 10 cm cell culture dish before re-plating into a XF24 cell culture microplate, to ensure equal cell input to the control un-induced H9 CHO cells.

For permeabilized CHO cell respirometry, cells were permeabilized with rPFO reagent (Agilent \#102504--100) in a cytosol-like buffer containing 70 mM sucrose, 220 mM mannitol, 10 mM KH~2~PO~4~, 5 mM MgCl~2~, 2 mM HEPES, 1 mM EGTA and 0.2% BSA(w/v), with pH adjusted to 7.4 by KOH.

The standardized procedure measuring mitochondrial respiration on an XF platform can be found at the following website: [https://www.agilent.com/cs/library/technicaloverviews/public/5991-7157EN.pdf.](https://www.agilent.com/cs/library/technicaloverviews/public/5991-7157EN.pdf)

ER ATP assay in saponin-permeabilized H9 CHO cells measured by luciferase assay {#s4-12}
-------------------------------------------------------------------------------

H9 CHO cells were seeded onto 96-well plates at a density of fifty thousand cells per well and were allowed to attach and grow overnight to reach eighty to ninety percent confluency. On the day of assay, cells were first permeabilized with artificial cytosol-like buffer containing 75 µg/mL saponin. The buffer contains 70 mM sucrose, 220 mM mannitol, 10 mM KH~2~PO~4~, 5 mM MgCl~2~, 2 mM HEPES, 1 mM EGTA (unless when it was intentionally omitted) and 0.2% BSA(w/v), with pH adjusted to 7.4 by KOH. In addition, 10 mM pyruvate and 1 mM malate plus 2 mM ADP were added to maintain mitochondria respiration upon membrane permeabilization. Ca^2+^ concentrations in cytosol-like buffer were controlled by adding increasing amounts of CaCl~2~. Free \[Ca^2+^\] was estimated according to a protocol previously described ([@bib30]) ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). H9 cells were further incubated at 37°C in a cell culture incubator for 20--30 min, before the buffer was removed by taping the cell culture plate on a stack of dry paper towels. *ATPLite* kit (Perkin Elmer, Cat \# 6016943) was used to quantify the ATP store in permeabilized H9 cells, following the manufacturer's protocol. Bioluminescence signals were recorded on a *SpectraMax i3x* multi-mode detection platform (Molecular Devices), with an integration time of 500 milliseconds per well. ATP measurements from eight to ten wells were averaged to plot the final graph under all conditions. Tg (0.25--1 µM) and oligomycin (1--2.5 µM) were used in inhibit SERCA and ATP synthase respectively, as indicated.

In addition, the same *ATPLite* kit was used to measure total cellular ATP. For [Figure 1H](#fig1){ref-type="fig"} and [Figure 1---figure supplement 7A](#fig1s7){ref-type="fig"} and [Figure 1---figure supplement 8A](#fig1s8){ref-type="fig"}, H9 CHO cells were incubated for 1 hr in serum-free DMEM medium containing substrates supporting only OxPhos (Seahorse BioSciences, Cat. \#100965 with 1 mM sodium pyruvate supplemented), in experiments where glucose supplementation effect was tested.

*SLC35B1* knock-down in HeLa cells {#s4-13}
----------------------------------

For siRNA mediated knock-down of *SLC35B1* in HeLa cells, the following siRNA sequence, targeting the *SLC35B1* 3'-UTR, was used: 5'-GAG ACU ACC UCC ACA UCA A dTdT-3'. Control cells were treated with a scrambled siRNA of the following sequence: 5\'-AGG UAG UGU AAU CGC CUU G dTdT-3\'. Cells were transfected at a confluency of \~ 70% using TransFast transfection reagent (Promega GmbH, Mannheim, Germany) according to the following protocol: 1.5 µg ERAT4.01 plasmid, 0.12 nmol of siRNA against *SLC35B1* 3'-UTR or control siRNA and 3 µl of TransFast were added to 1 ml of FCS free DMEM medium. Mixture was incubated for 15 min at room temperature before applying onto adherent HeLa cells, replacing cell growth media containing 10% FCS. After 4 hr, transfection mixture was exchanged for DMEM plus 10% FCS. Cells were incubated for another 48 hr in a humidified incubator at 37°C prior to imaging analysis. Similar transfection procedures were used for INS1 and CHO cells using commercially available siRNAs from Qiagen.

Detection of intracellular Ca^2+^ levels by chromogenic assay in CHO lysates {#s4-14}
----------------------------------------------------------------------------

Total intracellular Ca^2+^ levels were measured by the O-Cresolphtalein (OCPC) chromogenic method, using components provided in a Ca^2+^ Assay Kit (Adipogen Corp., Cat \# JAI-CCA-030). Briefly, H9 CHO cells were grown to 70% confluency in 10 cm cell culture dishes and induced to express F8 with 5 µM SAHA for 22 hr. Cells were trypsinized, gently centrifuged and re-suspended in 1 mL complete culture medium. After cell density quantification, six million cells were dispensed into a separate set of 1.5 mL Eppendorf tubes for Ca^2+^ quantification. Cells were pelleted by centrifugation, washed once with Ca^2+^-free HBSS, and lysed immediately in 120 µL of 3% trichloroacetic acid on ice for 30 min, with intermittent vortexing. Cell lysates were further clarified by centrifugation at 6,000 rpm for 15 min using a bench-top Eppendorf Centrifuge (Model \# 5415R). Cleared supernatants were used for OCPC-based Ca^2+^ level detection as per manufacturer's instructions. Optical densities (OD at 570 nm) were read and recorded by a *VERSAmax* microplate reader (Molecular Devices) and Ca^2+^ concentrations were determined by the Ca^2+^ standard curve provided in the OCPC kit.

Western blot analysis {#s4-15}
---------------------

CHO cells were grown on multiple-well plates and treated with compound in alpha MEM growth medium ([@bib9]). Cells were harvested by direct lysis with RIPA buffer (150 mM NaCl, 50 mM Tris pH 7.4, 1% Triton X100, and 0.5% Sodium Deoxycholate). Cell lysates were pre-cleared by centrifugation and protein concentration were determined by Bio-Rad's Dc protein assay kit. Total cellular protein (10--20 µg) was loaded onto a Bio-Rad's precast SDS-PAGE gel for electrophoresis and subsequent semi-dry transfer to a nitrocellulose membrane, as previously described^15^. Primary antibodies used for immunoblotting are summarized in '*Construction and validation of H9 CHO cell line*' section.

Quantification and Statistical Analysis {#s4-16}
---------------------------------------

Flow cytometry data recorded by cytometers were saved as FCS 3.1 files and analyzed by FlowJo software (Version: 10.2, FlowJo LLC) on a Mac platform. A ratio parameter was defined using the FlowJo's '*Derived Parameters*' function, as defined above for each reporter. Normality of the derived parameter was subsequently checked by plotting a histogram for every ratio parameter. Furthermore, the geometric means of fluorescence intensities (gMFI) were applied for population statistics analysis, as ratiometric parameters usually follow a log-normal distribution. Typically, statistics from a reporter positive population of more than 3000 single cells at any given time point were used to ensure data reproducibility.

Colocalization by *Pearson correlation* analysis of CHO cells expressing *ERAT4.01^N7Q^* and *TagRFP* was performed using ImageJ software, with plugins '*Colocalization Test*' and '*Fay Randomization*' algorithms. Prior to the analysis, images were further 2D-deconvoluted using MetaMorph software (Molecular Devices, San Jose, USA).

Compartmental ATP and/or Ca^2+^ levels were compared using the '*Ordinary Two-way ANOVA*' function provided by GraphPad's Prism software (Ver: 7.0), with alpha level of 0.05. Time and compounds were assumed two independent parameters for ANOVA analysis. *Dunnett's* multiple comparisons test was subsequently performed for comparison between individual groups versus diluent control (DMSO or PBS), or control group as indicated for particular experiments. Statistical significance was expressed as following: *n.s* - not significant; \* - p≤0.05; \*\*- p≤0.01; \*\*\*- p\<0.001; \*\*\*\* - p\<0.0001.

Supplemental Information {#s4-17}
------------------------

Supplemental information includes pdf files for '[Supplementary file 1](#supp1){ref-type="supplementary-material"} and '[Supplementary file 2](#supp2){ref-type="supplementary-material"}'.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Mitochondria supply ATP to the ER through a mechanism antagonized by cytosolic Ca^2+^\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Suzanne Pfeffer as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Richard Zimmermann (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The authors report new findings concerning the control of ER energy homeostasis by cytosolic calcium levels. They conclude that the ATP supply of the ER is mostly generated by mitochondrial OxPhos. In addition, they claim that cytosolic Ca^2+^ controls the ER ATP import, which is mediated by SLC35B1/AXER and that the elicitation of protein misfolding in the ER increases the ATP demand.

Essential revisions:

The major conclusions are of sufficient interest for publication in *eLife*, as the work addresses important aspects of ER biology. However, there are some issues that need to be addressed before the paper can be recommended for publication in *eLife*.

1\) The link between *Slc35B1* and *CaATiER* is weak. The data on HeLa cells do not support the *CaATiER* model and there are no data on SLC35B1/AXER for the other two cell lines. Therefore, additional work is required to provide this link or, alternatively, to identify the ATP carrier that is linked to *CaATiER* in INS1 or CHO cells.

2\) An in-depth analysis of the role of *Slc35B1* is needed to strengthen the study. It is required to show that *Slc35B1* is indeed the one and only ATP transporter to the ER. The analysis of a cytoplasmic calcium sensitivity/dependence of the *Slc35B1* may provide some useful information.

3\) The discrepancies between the old and new results in INS1 cells need to be explained.

These criticisms of the work are listed in great detail in the reviews, which are attached in full. In addition, the reviewers offered many thoughtful and constructive suggestions to improve the manuscript.

Reviewer \#1

In this manuscript, Kaufman, and colleagues reported the identification how ATP enters the ER lumen through a cytosolic calcium-antagonized mechanism, or, as proposed by the authors a *CaATiER* (Ca-Antagonized Transport into ER). They report that a calcium gradient across the ER membrane is necessary for ATP transport into the ER suggesting that cytosolic calcium signaling is coupled with ATP transport to the ER. They propose an attractive explanation that cytosolic increased calcium inhibits ATP import into the ER lumen. This is to reduce ATP consumption by ER. They also report that ATP abundance in the ER and traffic from mitochondria is sensitive to inhibitors of the oxidative phosphorylation and ER protein misfolding. These findings link that ATP usage in the ER with mitochondrial oxidative phosphorylation and glycolysis. These are very interesting findings and provide important and novel information on ATP metabolism, sources and regulation in the ER. This is an interesting study that significantly advances our knowledge about ER homeostasis and its links to cellular metabolism. It will certainly generate broad interest and further research in this important field of cell biology.

The biochemical/biophysical and cell biological assays demonstrating ATP production and transport are rather extensive and elegant using state-of-the-art techniques and ERTA probe for measurement of ER organellar ATP levels.

However, a few important points remain to be addressed by the authors.

The authors should define what they mean by \"Ca^2+^ gradient across the ER membrane\". Is there a particular threshold of the gradient? Is this highly regulated process?

The role of cytoplasmic calcium is intriguing. Do the authors have any evidence for a specific signaling event that drives cytosolic calcium-dependent ATP movement? Is *slc35b1* a calcium binding protein? Is a specific calcium gradient required? Could this be a clue to the \"memory\" of the transporter (subsection "ER ATP import requires a Ca^2+^ gradient across the ER membrane")?

I wonder why do authors exclusively use FACS analysis for the ERTA probe? Has there been any attempts to carry out a single cell analysis? This would provide additional validation of the data and allow real-time analysis of molecular movements.

The authors should consider using BAPTA-AM (or other cytoplasmic calcium chelators) in life cells to control cytoplasmic calcium in order to complement saponin permeabilized cell analyses.

What is the source of calcium in the cytoplasm that affects ATP transport? Is a store-operated calcium entry involved in addition to the ER?

Is the mitochondria associated membrane involved in the process? Latest report on the role of IRE1 in control of calcium movement between ER and mitochondria (PMID:31110288) indicates a link between UPR, ER, mitochondria and calcium. Is there a link to ATP transport reported here? Can this be documented? This, perhaps, may help to document that ATP and calcium movements are indeed operate or not as two distinct modes.

Reviewer \#2

The manuscript by Yong et al. titled \"Mitochondria supply ATP to the ER through a mechanism antagonized by cytosolic Ca^2+^\" addresses aspects of ER energy homeostasis and its regulation, in particular by cytosolic calcium levels. Yong and colleagues determined the crosstalk between the energy producing mitochondria and the ATP consuming ER lacking an autonomous ATP regenerating machinery. Based on a series of cell-based assays and employing a multitude of fluorescent sensors in combination with all sorts of pharmacological interventions in three cell lines from different species the authors conclude, that

-- the ATP supply of the ER is mainly covered by mitochondrial OxPhos

-- cytosolic Ca^2+^ regulates the ER ATP import, which is mediated by SLC35B1/AXER

-- that induction of protein misfolding in the ER elevates its ATP demand.

Those are indeed interesting findings that further our understanding of ER homeostasis and regulatory mechanisms, granted. However, the manuscript lacks some consistency both experimentally and visually. We would appreciate if the authors could address the following major and minor comments. In the absence of respective revisions, the work does clearly not deserve the rating \"outstanding\", which is a prerequisite for publication in *eLife*.

Abstract /Significance:

1\) The Abstract gives the unwarranted impression that HeLa cells were used throughout the study, i.e. that the so-called calcium antagonized ATP transport into the ER of hamster CHO- and rat INS1-cells was also observed for HeLa cells, which is at odds with Figure 3F of this manuscript (as well as findings by Vishnu et al., 2014, and Klein et al., 2018). Actually, Vishnu et al., 2014 reported a similar phenomenon as for HeLa cells also for INS1-cells. Also see point 23 below.

2\) The significance statement gives the unwarranted impression that it was shown for all three cell lines that the calcium antagonized ATP transport into the ER is mediated by SLC35B1/AXER. In fact, only HeLa cells were used for the *slc35b1* knock down experiment. Thus, it remains an open question how calcium antagonized ATP transport into the ER of CHO- and INS1-cells is mediated. After all, Vishnu et al., 2014 as well as Depaoli et al., 2018 -- both involving R. Malli as senior author -- reported that there are cell type-specific effects involved.

3\) The authors emphasize the anti-Warburg effect reflecting an increase in mitochondrial OxPhos and decrease in glycolysis. If I understand correctly, the drop in glycolysis is only shown in Figure 4---figure supplement 1 indirectly by inhibiting OxPhos in stressed and unstressed CHO cells.

-- The figure should be a main figure, if its implications deserve mentioning in Abstract and significance statement.

-- Is there a better way to address the efficiency of glycolysis in unstressed and stressed cells directly using the Seahorse (e.g. like the ECAR measurements shown in Figure 1---figure supplement 4B)?

Introduction

4\) The Introduction is too short and superficial lacking a somewhat more comprehensive background on the topic of ER ATP import. It appears to be somewhat outdated. Maybe a few more references could also be cited.

5\) Furthermore, when first talking about ER-ANT it should be pointed out that it is restricted to plants and the respective reference should be given.

6\) In addition, the statement that \"the mammalian equivalent of ER-ANT1 had remained elusive until a recent publication identified SLC35B1 as the putative mammalian ATP transporter\" is misleading, as no orthologs of ER-ANT1 were detected in mammals or yeast and orthologs of SLC35B1 exist in plants and yeast.

Results

7\) The Results section needs a substantial re-arrangement. It appears way too crowded and lacks a continuous, smooth flow. For example:

-- Why do the authors introduce the inducible H9 CHO model in Figure 1A and 1B to demonstrate the localization of the ERAT probe being independent from ER stress. This should be added to Figure 4 when the authors actually show the increase of F8 production in response to SAHA treatment and the subsequent activation of UPR. The rest of the data for Figure 1 (1C-1H) was generated using the CHO model.

-- Figure 1C should be moved to the supplement, its basic knowledge. The \"formula\" within the ER (ATP supply -- ATP consumption = ATP status proportional to ERAT FRET) should be displayed differently.

-- Figure 2 starts with INS1 cells and continues with CHO cells. Maybe it\`s better to show only the CHO cells and put the data with the INS1 cells reacting similarly as the CHO cells to the supplement. Comparing Figure 2A-D with 2E-H two parameters were changed, cell type and SERCA inhibitor.

8\) It would be important to show at least once that BiP activity is compromised under conditions of OxPhos inhibition in CHO- and INS1-cells, i.e. to provide independent biochemical evidence to back up the imaging data, e.g. in connection with Figure 1.

9\) Results section: \"2-DG administration did not negatively affect the OCR\". This is misleading as the 2-DG treatment does affect the OCR positively, which the authors later write. The corresponding red 2-DG lines in Figure 1D and Figure 1---figure supplement 4B lack the standard error for a meaningful comparison to the control.

10\) Figure 1E and 1F do not correlate well with regard to the value numbers and tiny error bars in 1F. Figure 1E shows no error bar. What would be the 0 min start value in Figure 1E? Is it the same for the populations?

11\) Results section and Figure 1E: \"flow-cytometry circumvents photo-bleaching\"; But in Figure 1E the DMSO control shows a drop in ER ATP levels as pronounced as the OxPhos inhibitors over time. Is that photo-bleaching or what effect causes the drop in ATP levels over the 30 min time frame of the measurement?

12\) Why was the vehicle control DMSO used in 0.01% (Figure 1---figure supplement 5) and 1% (Figure 1---figure supplement 6). The latter is way too high to ensure measurements under physiological conditions.

13\) Results subsection "ER ATP comes from Mitochondrial OxPhos in CHO cells" paragraph three and Figure 1G: IAA increases ER ATP levels, but in Figure 1---figure supplement 6B 2-DG reduces ER ATP levels. Can the 2-DG treatment, which is probably a more specific glycolysis inhibitor than IAA, be done with the flow cytometry assay as well? In fact, Iodoacetamide should not be considered as a specific inhibitor of glyceraldehyde phosphate dehydrogenase (GAPDH), it alkylates all cysteine residues.

14\) Results section: \"Finally, the observations made in H9 CHO cells were completely reproduced in CHO cells that do not express human F8\"

This is unclear to me and leads to several questions.

-- Are all previous measurements performed in \"stressed\" CHO cells?!

-- Why is the basal ER ATP level (FRET ratio) in Figure 1---figure supplement 7D for DMSO much higher than other measurements (e.g. Figure 1E, 2E, 2E S2C). The stressed cells should not be considered physiological measurements under steady state.

-- In Figure 1---figure supplement 7D for DMSO the measurement is constant over time in contrast to Figure 1E and many other vehicle control measurements. Why?

15\) Why is the 0 min time point so often omitted in figures?

16\) Figure 2: H9 CHO cells with or without induction of F8?

17\) It is often unclear how many cells were used in the fluorescence ratiometric analysis/ measurements?

18\) Subsection "Cytosolic Ca^2+^ inhibits ATP import into the ER": \"ER ATP usage arrest\"

How would SERCA inhibition cause an ATP usage arrest? Wouldn\'t misfolding or ER stress drive ATP consumption by chaperones?

19\) Figure 3H: Writing too small and figure too crowded/complicated. Reduce irrelevant information.

20\) Figure 4A: Too small

Would it not be better, having the data from Figure 1A and 1B together with the Western blot panel that demonstrates F8 synthesis upon SAHA treatment and the inductions of UPR?

21\) Subsection "Protein misfolding in the ER increases both ER ATP dependence on OxPhos and Tg-triggered Ca^2+^ mobilization into mitochondria.": it is unclear how long the cells were pre-treated with SAHA for stress induction.

22\) Figure 4 I and J: Highlight the trace of population mean.

Discussion

23\) Subsection "Cytosolic Ca^2+^ regulates ATP import into the ER" and others: \"ER Ca^2+^ release with a transient ER ATP increase (Vishnu et al., 2014) (and repeated in Figure 3F) could reflect a temporary reduction in ER ATP consumption, rather than reflecting the luminal Ca^2+^ sensitivity of the ER ATP import machinery.\" It appears (e.g. based on Vishnu et al., 2014) that the calcium depletion of the ER slightly precedes the initial increase in ATP level. According to the model by Yong et al. this would already inhibit SLC35B1 and prevent further ATP uptake. Yet, initially ATP levels rise in response to SERCA inhibition. In addition, the authors write \"a temporary reduction in ER ATP consumption\". How would the reduction of ATP consumption increase the ATP level? Wouldn\'t it cause a stagnation of the ATP levels without the ATP transporter being active?

24\) In general, we wonder how the observed role of cytosolic AMPK in Ca^2+^ coupled ER ATP increase (Vishnu et al., 2014) fits into the model, which is described here, and why this was not addressed or at least discussed here.

10.7554/eLife.49682.030

Author response

> Essential revisions:
>
> The major conclusions are of sufficient interest for publication in eLife, as the work addresses important aspects of ER biology. However, there are some issues that need to be addressed before the paper can be recommended for publication in eLife.

The wise and encouraging comments by the editors are greatly appreciated.

We concur with Drs. Sonenberg and Pfeffer that regulation governing ATP supply to the ER constitutes the fundamental aspect of ER biology, esp. for energy homeostasis. Our discovery that cytosolic Ca^2+^ playing such a role witnesses, again, the elegant balancing mechanism of the intricate homeostatic control, inside a mammalian cell.

> 1\) The link between Slc35B1 and CaATiER is weak. The data on HeLa cells do not support the CaATiER model and there are no data on SLC35B1/AXER for the other two cell lines. Therefore, additional work is required to provide this link or, alternatively, to identify the ATP carrier that is linked to CaATiER in INS1 or CHO cells.

First, while SLC35B1 is a necessary component for ATP supply to the ER, as demonstrated by Klein et al., we believe it is not sufficient to explain the *CaATiER* phenomenon. By analogy, for the plasma membrane ATP-sensitive K^+^~ATP~ channel, the ATP-sensing subunits SUR1/SUR2A/SUR2B are separate entities from the K^+^ channel (encoded by the KCNJ-8/-11 genes).

In this revision, we now demonstrate that *Slc35b1* knockdown attenuated the *CaATiER* phenomenon in both CHO and INS1 cells.

To elaborate:

1\) Using the semi-intact CHO cell system, we confirmed that *Slc35b1* knockdown reduced basal ER ATP levels, and attenuated *CaATiER*. The figure is now available as main Figure 3E, and the more detailed results are also provided in Figure 3 ---figure supplement 2.

2\) We also demonstrated that *Slc35b1* knockdown reduced basal ER ATP levels and attenuated *CaATiER* using single cell FRET imaging. The figures are now displayed as Figure 3 ---figure supplement 3 (A to F).

These observations further support our model in Figure 3H.

> 2\) An in-depth analysis of the role of Slc35B1 is needed to strengthen the study. It is required to show that Slc35B1 is indeed the one and only ATP transporter to the ER. The analysis of a cytoplasmic calcium sensitivity/dependence of the Slc35B1 may provide some useful information.

We believe our data presented in Figure 3---figure supplement 2 and Figure 3---figure supplement 3 fully support the model that SLC35B1 is a necessary component for ATP import into the ER. However, as important as SLC35B1 is for ER ATP supply, we cannot state that it is the "one and only ATP transporter into the ER". As in a recent review (Depaoli et al., 2019), we believe that additional pathways might supply the ER with ATP. See Figure 3 in Depaoli et al., 2019.

Among the above proposed mechanisms, based on our results, we believe the SLC35B1 ATP/ADP translocase constitutes the major ATP import mechanism to the ER, while the retrograde import from the Golgi apparatus constitutes another important ATP supply. The latter may explain why *Slc35b1* knockdown is not lethal for the cell lines we have tested so far. In addition, we are unsure if the translocon channels or non-specific transporters (shaded in blue and green) play any role for meaningful ATP import into the ER.

To analyze the cytoplasmic calcium sensitivity/dependence of *Slc35B1*, we performed Ca^2+^ dose response using the semi-intact H9 CHO cell system which showed that Ca^2+^ sensitivity is \~ 0.5 -- 2 µM for the *CaATiER* mechanism in mammalian cells. This result is now provided as Figure 3---figure supplement 5.

In addition, importantly, the nice paper by Klein et al. (Klein et al., 2018) elegantly demonstrated that SLC35B1 expression alone did not confer the Ca^2+^ responsiveness (when ectopically expressed in *E. coli*, c.f. Table 1 by Klein et al., cited below), which suggests that the SLC35B1 protein is the ATP/ADP translocation channel, but does not encode the Ca^2+^ responsiveness element. However, in the absence of data, we refrain from further speculation.

> 3\) The discrepancies between the old and new results in INS1 cells need to be explained.

We do not feel that the "old" and new results are different from each other. Please note that in the study of Vishnu et al., 2014, the time frame of BHQ treatment of INS-1 cells was rather short (\~ 3 minutes, in the left panel from Figure S3A of Vishnu et al.) prior to the depletion of ER Ca^2+^ by the administration of the IP3 generating agonists CCh and ATP. In the current study we investigated and followed the BHQ effect on ER ATP content for more than 30 minutes, and still observed an increase in ER ATP at the start of the BHQ treatment, shown in Figure 3---figure supplement 3A.

> These criticisms of the work are listed in great detail in the reviews, which are attached in full. In addition, the reviewers offered many thoughtful and constructive suggestions to improve the manuscript.
>
> Reviewer \#1
>
> \[...\] The authors should define what they mean by \"Ca^2+^ gradient across the ER membrane\". Is there a particular threshold of the gradient? Is this highly regulated process?

The "Ca^2+^ gradient across the ER membrane" means an uneven distribution of Ca^2+^ cation on the two sides of the ER membrane, where on the cytosolic Ca^2+^ level is low (\~ 100 nM) while in the ER lumen Ca^2+^ is high (\~ 1 mM). It is so-named by analogy to the "proton gradient" across the mitochondrial inner membrane.

As for the excellent point to determine the "Ca^2+^ gradient" threshold, we demonstrated experimentally, using the semi-intact CHO H9 cell system, that the cytosolic Ca^2+^ concentration needed to trigger *CaATiER* is within the high nM to low µM range of free Ca^2+^, as shown in our response to Q2 above. Unfortunately, it is technically challenging to decide such thresholds in an intact cell.

> The role of cytoplasmic calcium is intriguing. Do the authors have any evidence for a specific signaling event that drives cytosolic calcium-dependent ATP movement? Is slc35b1 a calcium binding protein? Is a specific calcium gradient required? Could this be a clue to the \"memory\" of the transporter (subsection "ER ATP import requires a Ca^2+^ gradient across the ER membrane")?

We did not set out to determine whether the *CaATiER* mechanism is mediated by the Ca^2+^ responsiveness of SLC35B1/AXER. In fact, Klein et al. (Klein et al., 2018) suggested that SLC35B1 alone did not confer Ca^2+^ responsiveness when ectopically expressed in *E. coli* (Table 1 by Klein et al), which suggests that SLC35B1 is solely the ATP/ADP translocation channel.

However, in the absence of data, we refrain from further speculate.

> I wonder why do authors exclusively use FACS analysis for the ERTA probe? Has there been any attempts to carry out a single cell analysis? This would provide additional validation of the data and allow real-time analysis of molecular movements.

We relied heavily on FACS as the population statistics is robust and highly reproducible.

In addition, we consider the microscopy-based FRET assays as "single cell analyses", as suggested by this reviewer, which are shown in Figures 2, 3 and 4. A good example in point is Figure 2 B -- D and J. Importantly, the results from both methods are highly consistent.

> The authors should consider using BAPTA-AM (or other cytoplasmic calcium chelators) in life cells to control cytoplasmic calcium in order to complement saponin permeabilized cell analyses.

As suggested by this reviewer, we now show the effect of BAPTA-AM effect by microscopy-based and flow-based ER ATP assays. The results are summarized below:

A\) While the initial Ca^2+^ chelating by BAPTA-AM supported our *CaATiER* model in that ER ATP FRET signal went up transiently, we caution the conclusion that BAPTA-AM is an *intracellular* Ca^2+^ chelator and therefore the result cannot be interpreted as a cytoplasmic Ca^2+^ chelating effect.

B\) Prolonged BAPTA-AM treatment (5 µM x 90min) significantly reduced ER ATP, as detected by flow-cytometry, shown in [Author response image 1](#respfig1){ref-type="fig"}.

![](elife-49682-resp-fig1){#respfig1}

> What is the source of calcium in the cytoplasm that affects ATP transport? Is a store-operated calcium entry involved in addition to the ER?

From results in Figure 2F, and Figure 2J, it appears that Ca^2+^ release from the ER pool is sufficient, as extracellular chelation by EGTA did not abolish the *CaATiER* phenomenon.

We conclude that store-operated calcium entry (SOCE) is not required based on the current data. Whether SOCE is involved in an intact cell under physiological conditions is an excellent question for future investigation.

> Is the mitochondria associated membrane involved in the process? Latest report on the role of IRE1 in control of calcium movement between ER and mitochondria (PMID:31110288) indicates a link between UPR, ER, mitochondria and calcium. Is there a link to ATP transport reported here? Can this be documented? This, perhaps, may help to document that ATP and calcium movements are indeed operate or not as two distinct modes.

This is another excellent point from this reviewer. The topic of "mitochondria-associated membrane" is a broad field to address. We have now performed the following experiment, using established tools, as suggested by this reviewer.

By applying the artificial ER-to-mito linkers characterized by Csordas et al. (Csordas et al., 2010), we failed to detect any meaningful changes in the oxygen consumption rates (OCR) after linker ligation by Rapamycin (data in [Author response image 2](#respfig2){ref-type="fig"} in panel B after "Rapa"). Furthermore, unfortunately, the design of these fluorescence linkers (CFP-FRB-ER and RFP-FKBP-mito, respectively) prevented our ER ATP analysis using our ERAT protein that employs the same CFP as the FRET donor. Nevertheless, we agree with this reviewer that his/her question is an important direction for future investigation.

![Left panel -- Illustration of linkers used; Right panel -- OCR results before and after linkers ligation by Rapa.\
DT-8 = Double transfected clone 8, with both linkers present, experimental group. AR-6/-10\* = AKAP1-mRFP, with only mito-linker present, clone-6/-10. \*AR clones served as control clones.](elife-49682-resp-fig2){#respfig2}

> Reviewer \#2
>
> \[...\] Those are indeed interesting findings that further our understanding of ER homeostasis and regulatory mechanisms, granted. However, the manuscript lacks some consistency both experimentally and visually. We would appreciate if the authors could address the following major and minor comments. In the absence of respective revisions, the work does clearly not deserve the rating \"outstanding\", which is a prerequisite for publication in eLife.

We thank reviewer \#2 for his positive comments. We would like to clarify the second conclusion by reviewer \#2, i.e. "cytosolic Ca^2+^ regulates the ER ATP import, which is mediated by SLC35B1/AXER". While Klein et al. demonstrated (Klein et al., 2018) SLC35B1/AXER mediates ER ATP import, and in this revision we provide analysis in CHO, HeLa and INS-1 cells that SLC35B1 is indeed indispensable for ER ATP import. We do not claim that the Ca^2+^-responsiveness is also conferred by SLC35B1, as we elaborated above in Q2 to the editors.

To avoid this confusion, we modified our working hypothesis cartoon to isolate Ca^2+^-sensing element as an independent entity (now as Figure 3H). In the absence of data, we refrain from further speculation on the Ca^2+^-responsiveness of SLC35B1.

> Abstract /Significance:
>
> 1\) The Abstract gives the unwarranted impression that HeLa cells were used throughout the study, i.e. that the so-called calcium antagonized ATP transport into the ER of hamster CHO- and rat INS1-cells was also observed for HeLa cells, which is at odds with Figure 3F of this manuscript (as well as findings by Vishnu et al., 2014, and Klein et al., 2018). Actually, Vishnu et al., 2014 reported a similar phenomenon as for HeLa cells also for INS1-cells. Also see point 23 below.

We thank Dr. Zimmermann for this comment.

By applying the semi-intact CHO cell assay, which was not available in 2014, we are now confident that cytosolic Ca^2+^ plays an inhibitory role on ER ATP import. The result is now available as Figure 3E.

In addition, microscopy-based imaging also shows that cytosolic Ca^2+^ attenuates ER ATP import in all three cell lines, CHO/HeLa/INS-1. The results are presented in Figure 3---figure supplement 3, and also displayed above in response to Q2 of the editors.

In addition, in the original publication Vishnu et al. cautiously concluded "the Ca^2+^-coupled ER ATP increase is independent of the mode of Ca^2+^ mobilization and controlled by the rate of ATP biosynthesis" (Vishnu et al., 2014). Nevertheless, while we confirmed that the initial ER ATP increase is highly reproducible in HeLa (\<10 min in our Figure 3F, as well as in Vishnu et al., 2014 and Klein et al., 2018) and INS-1 cells, it does not represent the long-term ER ATP change in response to SERCA inhibition by BHQ. We are pleased to have faithfully recorded the dynamic changes in ER ATP, which shows cell-type dependent variation as suggested by the reviewer.

> 2\) The significance statement gives the unwarranted impression that it was shown for all three cell lines that the calcium antagonized ATP transport into the ER is mediated by SLC35B1/AXER. In fact, only HeLa cells were used for the slc35b1 knock down experiment. Thus, it remains an open question how calcium antagonized ATP transport into the ER of CHO- and INS1-cells is mediated. After all, Vishnu et al., 2014 as well as Depaoli et al., 2018 -- both involving R. Malli as senior author -- reported that there are cell type-specific effects involved.

We agree with Dr. Zimmermann that there are cell-type specific effects involved immediately upon SERCA inhibition. Now with the *CaATiER* phenomenon confirmed in all three cell lines, we conclude:

1\) The *CaATiER* phenomenon is not cell type-dependent, as shown in Figure 3F (HeLa cell) and Figure 3---figure supplement 3 (A and D, INS-1 and CHO H9 cells, respectively).

2\) There is a short-term transient increase in ER ATP after SERCA inhibition which may result from arrest of ER ATP usage. However, the long-term effects on ER ATP depletion are consistent in all three cell lines as shown in Figure 3F and Figure 3---figure supplement 3 A and D.

3\) Intracellular Ca^2+^ trafficking is a complex process in itself, and we are able to confirm the *CaATiER* phenomenon using semi-intact CHO cells where we confirmed the cytosolic Ca^2+^ effect is inhibitory for ER ATP import, as demonstrated in Q2 response to the editors.

> 3\) The authors emphasize the anti-Warburg effect reflecting an increase in mitochondrial OxPhos and decrease in glycolysis. If I understand correctly, the drop in glycolysis is only shown in Figure 4---figure supplement 1 indirectly by inhibiting OxPhos in stressed and unstressed CHO cells.
>
> -- The figure should be a main figure, if its implications deserve mentioning in Abstract and significance statement.

We are confident about the "anti-Warburg effect" in CHO H9 cells.

However, we refrain from further speculation by considering other aspects of cell metabolism, esp. glucose metabolism.

> -- Is there a better way to address the efficiency of glycolysis in unstressed and stressed cells directly using the Seahorse (e.g. like the ECAR measurements shown in Figure 1---figure supplement 4B)?

ECAR is not an optimal measure for glycolysis, esp. for CHO cells with a vigorous TCA cycle that produces organic acids. In order to support our claim that glycolysis is reduced in stressed cells, we performed flow-cytometry using 2-NBDG labeling to measure glucose uptake, upon FVIII induction with HDAC inhibitors, NaB or SAHA. The results are consistent with our hypothesis that ER stress reduces glucose uptake in CHO H9 cells and are now shown as Figure 4---figure supplement 2.

> Introduction
>
> 4\) The Introduction is too short and superficial lacking a somewhat more comprehensive background on the topic of ER ATP import. It appears to be somewhat outdated. Maybe a few more references could also be cited.

Introduction" was modified as suggested.

> 5\) Furthermore, when first talking about ER-ANT it should be pointed out that it is restricted to plants and the respective reference should be given.

Modified as suggested.

> 6\) In addition, the statement that \"the mammalian equivalent of ER-ANT1 had remained elusive until a recent publication identified SLC35B1 as the putative mammalian ATP transporter\" is misleading, as no orthologs of ER-ANT1 were detected in mammals or yeast and orthologs of SLC35B1 exist in plants and yeast.

Modified as suggested.

> Results
>
> 7\) The Results section needs a substantial re-arrangement. It appears way too crowded and lacks a continuous, smooth flow. For example:
>
> -- Why do the authors introduce the inducible H9 CHO model in Figure 1A and 1B to demonstrate the localization of the ERAT probe being independent from ER stress. This should be added to Figure 4 when the authors actually show the increase of F8 production in response to SAHA treatment and the subsequent activation of UPR. The rest of the data for Figure 1 (1C-1H) was generated using the CHO model.

We apologize for the confusion, but the data for Figure 1 C to H panels were generated using the H9 CHO cells. Specifically, H9 CHO is an inducible cell system for FVIII production which has no UPR activation under basal conditions, as we demonstrated previously (Dorner et al., 1989) and here in *Figure 4A*.

To emphasize, the only experiment that used parental CHO cells (i.e. DUK clone) is in Figure 1---figure supplement 7D.

> -- Figure 1C should be moved to the supplement, its basic knowledge. The \"formula\" within the ER (ATP supply -- ATP consumption = ATP status proportional to ERAT FRET) should be displayed differently.

We thank Dr. Zimmermann for this suggestion. However, it appeared to us that not all readers may be familiar about ER ATP homeostasis so we have not moved this figure.

> -- Figure 2 starts with INS1 cells and continues with CHO cells. Maybe it\`s better to show only the CHO cells and put the data with the INS1 cells reacting similarly as the CHO cells to the supplement. Comparing Figure 2A-D with 2E-H two parameters were changed, cell type and SERCA inhibitor.

We thank Dr. Zimmermann for this suggestion. However, we strongly believe *CaATiER* is better supported by data from two cell lines, esp. from rat and Chinese hamster respectively, using two SERCA inhibitors that are structurally distinct. We were convinced by this comparison *CaATiER* is not a compound or cell type-specific artifact. Also, BHQ is selected for INS-1 cells due to its reversibility (Figure 2---figure supplement 1), while Tg is a highly efficient but irreversible SERCA inhibitor.

> 8\) It would be important to show at least once that BiP activity is compromised under conditions of OxPhos inhibition in CHO- and INS1-cells, i.e. to provide independent biochemical evidence to back up the imaging data, e.g. in connection with Figure 1.

We thank Dr. Zimmermann for this suggestion. The data highly consistent with our findings were shown in an earlier paper by Preissler et al., which we are citing for BiP trans-protomer formation in response to Tg.

In the above referenced publication, BiP oligomerization was proposed as a consequence from ATP depletion by Preissler et al., although in this reference the authors did not realize the ER ATP levels are controlled by cytosolic Ca^2+^.

However, we are also aware that BiP activity is not solely determined by ER ATP abundance, such as ERdj proteins, AMPylation and Ca^2+^, and is an inferior marker to our ERAT probe for determining ER ATP levels. For detailed discussions on this topic, please refer to relevant publications by Drs. Hendershot and Ron (Amin-Wetzel et al., 2017; Preissler et al., 2015; Wei et al., 1995).

> 9\) Results section: \"2-DG administration did not negatively affect the OCR\". This is misleading as the 2-DG treatment does affect the OCR positively, which the authors later write. The corresponding red 2-DG lines in Figure 1D and Figure 1---figure supplement 4B lack the standard error for a meaningful comparison to the control.

We agree with Dr. Zimmermann for the observation that 2-DG treatment does affect the OCR positively. However, the difference was not statistically significant as shown in Figure 1---figure supplement 4A, denoted by "n.s.".

The absence of standard error bars in Figure 1D was due to small error value. Using Prism software we received the message "For some points, the error bars would be shorter than the height of the symbol. In these cases, Prism simply does not draw the error bars."

> 10\) Figure 1E and 1F do not correlate well with regard to the value numbers and tiny error bars in 1F. Figure 1E shows no error bar. What would be the 0 min start value in Figure 1E? Is it the same for the populations?

Yes. Firstly, the 0min start value are all the same for every sample, as all tubes originated the same stock of reporter CHO cells, due to the experimental design available in our "Transparent reporting form", cited below for clarification. Specifically, for Figure 1E, all tubes with OxPhos toxins received the same batch of reporter cells from one cell suspension preparation (Step 6 -- Step 7), to ensure cell population homogeneity for comparison.

Secondly, flow cytometry-based FRET assay samples thousands of cells per time point.

For example, in Figure 1F, N equals 5388 for DMSO, 5298 for Oligo, 5313 for Rotenone, 5288 for FCCP groups, respectively. For Figure 1E, Prism software generated this message reading -- "For some points, the error bars would be shorter than the height of the symbol. In these cases, Prism simply does not draw the error bars."

![](elife-49682-resp-fig3){#respfig3}

> 11\) Results section and Figure 1E: \"flow-cytometry circumvents photo-bleaching\"; But in Figure 1E the DMSO control shows a drop in ER ATP levels as pronounced as the OxPhos inhibitors over time. Is that photo-bleaching or what effect causes the drop in ATP levels over the 30 min time frame of the measurement?

Firstly, the basal level drop is not from photobleaching, as every cell is only sampled once in a flow-cytometer.

Secondly, we think the baseline drift was derived from the vigorous shaking before cells were taken up by the flow cytometer, and we are working diligently to modify our procedures to mitigate such an effect, by reducing the shaking speed. The improvement is visible in Figure 2E and 2F. However, shaking step cannot be omitted for flow procedure.

> 12\) Why was the vehicle control DMSO used in 0.01% (Figure 1---figure supplement 5) and 1% (Figure 1---figure supplement 6). The latter is way too high to ensure measurements under physiological conditions.

The DMSO concentration was used to match the toxin dilution, in which the stock was prepared in. In addition, incubation of cell in 1% (vol/vol) DMSO over the period for 1 hr did not affect cell physiology.

> 13\) Results subsection "ER ATP comes from Mitochondrial OxPhos in CHO cells" paragraph three and Figure 1G: IAA increases ER ATP levels, but in Figure 1---figure supplement 6B 2-DG reduces ER ATP levels. Can the 2-DG treatment, which is probably a more specific glycolysis inhibitor than IAA, be done with the flow cytometry assay as well? In fact, Iodoacetamide should not be considered as a specific inhibitor of glyceraldehyde phosphate dehydrogenase (GAPDH), it alkylates all cysteine residues.

2-DG, if used for 2hrs, effectively depleted total cellular ATP (Figure 1---figure supplement 8B), due to its metabolism by hexokinase. The more imminent effect of 2-DG was tested and displayed in Figure 1---figure supplement 7.

We agree with Dr. Zimmermann that there is no single "glycolysis inhibitor" that only blocks ATP regeneration, as we discussed in our Introduction. For this reason, we used "no glucose" condition (Figure 1H, "Glucose" vs. "PBS") to confirm the effect of blocking glycolysis, where glucose addition for one hour had no effect.

> 14\) Results section: \"Finally, the observations made in H9 CHO cells were completely reproduced in CHO cells that do not express human F8\"
>
> This is unclear to me and leads to several questions.
>
> -- Are all previous measurements performed in \"stressed\" CHO cells?!

Please refer to our response to comment 7 for clarification.

H9 CHO is not considered "stressed" by basal level of F8 expression (Figure 4A), which is under the ER proteostasis control. We emphasize that only under prolonged treatment with a chemical inducer of FVIII transcription (HDAC inhibitor, e.g. SAHA or NaB) are the H9 CHO cells "stressed" (Figure 4A).

> -- Why is the basal ER ATP level (FRET ratio) in Figure 1---figure supplement 7D for DMSO much higher than other measurements (e.g. Figure 1E, 2E, 2E S2C). The stressed cells should not be considered physiological measurements under steady state.

The above explanation assures the basal H9 CHO cells are not "stressed".

In Figure 1---figure supplement 7D, CHO cells without F8 expression were used. The baseline FRET level is affected by the probe ERAT expression level, which is demonstrated in Figure 1---figure supplement 3A. Therefore, unlike the ATP luminescence assay by ATPLite kit, the baseline FRET signal cannot be used to calibrate ER ATP levels, and the difference in baseline FRET ratios are considered as clonal variation between the H9 and CHO cell clones. The change in FRET signal (*ΔFRET*) is more meaningful by design (Imamura et al., 2009).

> -- In Figure 1---figure supplement 7D for DMSO the measurement is constant over time in contrast to Figure 1E and many other vehicle control measurements. Why?

The CHO cells without F8 expression (i.e. DUK cells) use much less ATP in the ER, which correlates with less OxPhos activity in these cells. This observation is consistent with our notion that ER stress leads to an "*anti-Warburg*" effect.

> 15\) Why is the 0 min time point so often omitted in figures?

We provided an explanation in the response to comment 10. The 0 min cell population homogeneity was ensured by experimental design.

> 16\) Figure 2: H9 CHO cells with or without induction of F8?

H9 CHO cells used throughout Figures 1 to 3 were not induced for F8 expression, therefore they were not stressed.

> 17\) It is often unclear how many cells were used in the fluorescence ratiometric analysis/ measurements?

We provided the information in the "Transparent Reporting file", with the uploaded data files contained all the information needed for the statistical analysis.

We re-emphasize here that more than 2900 cells were used per data point for flow-analysis. We thought that would not contribute significantly to the message.

> 18\) Subsection "Cytosolic Ca^2+^ inhibits ATP import into the ER": \"ER ATP usage arrest\"
>
> How would SERCA inhibition cause an ATP usage arrest? Wouldn\'t misfolding or ER stress drive ATP consumption by chaperones?

It was our hypothesis for "ER ATP usage arrest", as many Ca^2+^-dependent ER chaperones also promote ATP hydrolysis, such as Calnexin and Calreticulin in cooperation with BiP.

Yes, protein misfolding should drive ATP consumption by chaperones. This partially explained why ER ATP drops in H9 cells upon matrix detachment and shaking, a condition that hampers OxPhos inside a cell (Grassian et al., 2011). However, ER Ca^2+^ depletion is not to be taken as equivalent to ER stress/protein misfolding induction, as shown recently (Szalai et al., 2018).

> 19\) Figure 3H: Writing too small and figure too crowded/complicated. Reduce irrelevant information.

We apologize for the methodology description. We modified our *CaATiER* model as suggested.

> 20\) Figure 4A: Too small
>
> Would it not be better, having the data from Figure 1A and 1B together with the Western blot panel that demonstrates F8 synthesis upon SAHA treatment and the inductions of UPR?

We apologize for the small font, as it is a repeat and confirmation of our previous observation (Dorner et al., 1989). We chose not to introduce WB result from SAHA treatment to avoid confusion between basal "unstressed" H9 CHO and the "stressed" H9 CHO.

> 21\) Subsection "Protein misfolding in the ER increases both ER ATP dependence on OxPhos and Tg-triggered Ca^2+^ mobilization into mitochondria.": it is unclear how long the cells were pre-treated with SAHA for stress induction.

We apologize for the omission. The SAHA treatment was 21 hrs for Figure 4 C and D, and this information was inserted in the figure legend.

> 22\) Figure 4 I and J: Highlight the trace of population mean.

Highlighted.

> Discussion
>
> 23\) Subsection "Cytosolic Ca^2+^ regulates ATP import into the ER" and others: \"ER Ca^2+^ release with a transient ER ATP increase (Vishnu et al., 2014) (and repeated in Figure 3F) could reflect a temporary reduction in ER ATP consumption, rather than reflecting the luminal Ca^2+^ sensitivity of the ER ATP import machinery.\" It appears (e.g. based on Vishnu et al., 2014) that the calcium depletion of the ER slightly precedes the initial increase in ATP level. According to the model by Yong et al. this would already inhibit SLC35B1 and prevent further ATP uptake. Yet, initially ATP levels rise in response to SERCA inhibition. In addition, the authors write \"a temporary reduction in ER ATP consumption\". How would the reduction of ATP consumption increase the ATP level? Wouldn\'t it cause a stagnation of the ATP levels without the ATP transporter being active?

We acknowledge that we do not completely understand the initial transient increase in the ERAT FRET signal in HeLa cells, except that it is highly reproducible in certain cell types (to a lesser extent INS-1, as shown in Figure 3---figure supplement 3A). We suspect there is a lag time in the cytosolic Ca^2+^ elevation to induce the *CaATiER* machinery, in the sequence of events in temporal order: SERCA inhibitor -\> ER Ca^2+^ uptake arrest -\> ER Ca^2+^ release -\> cytosolic Ca^2+^ accumulation -\> *CaATiER* activation.

Considering our semi-intact CHO cell result regarding the dose-response of \[Ca^2+\]^(Figure 3---figure supplement 5), we inferred that \~1 µM cytosolic Ca^2+^ isthe activation threshold, therefore it is reasonable to assume that *CaATiER* mechanism activation lagged behind the SERCA inhibitor administration.

> 24\) In general, we wonder how the observed role of cytosolic AMPK in Ca^2+^ coupled ER ATP increase (Vishnu et al., 2014) fits into the model, which is described here, and why this was not addressed or at least discussed here.

Wedid not further investigate the AMPK phosphorylation status here, partly in that we have more direct measure of ATP. We added discussions on the possible role of AMPK, in subsections "Cytosolic Ca2+ attenuates ATP import into the ER" and "ER protein misfolding increases the ER bioenergetic requirement for ATP from OxPhos".
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